SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/11

20110097261 - Amigo-2-inhibitors for treating, diagnosing or detecting cancer: The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with AMIGO-2 overexpression.... Agent:

20110097262 - Novel anti-cmet antibody: e

20110097263 - Kit formulation for the preparation of immunoliposome drug in combined bimodality radiochemotherapy: A kit formulation for the preparation of immunoliposome drug in combined chemotherapy and radionuclide therapy is disclosed, which consists: (1) a vial A containing proteins; (2) a vial B containing Traut's reagent; (3) a vial C containing DSPC, Cholesterol, mPEG-DSPE, Mal-DSPE-PEG and chemotherapy drug; (4) a vial D containing BMEDA,... Agent: Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan

20110097266 - Bombesin analog peptide antagonist conjugates: k

20110097267 - Compositions for imaging pain and stress in vivo: Briefly described, embodiments of the present disclosure relate to methods and compositions for imaging pain and/or stress in a subject and methods and compositions for treating associated conditions. In particular, the present disclosure relates to the use of labeled compounds to provide objective diagnosis of pain and/or stress, for imaging... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110097265 - Quantification method for remaining liver function and novel liver receptor imaging agent: A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of... Agent: Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan

20110097264 - Radiolabeling method using multivalent glycoligands as hepatic receptor imaging agent: A radiolabeling method using a multivalent glycoligand as hepatic receptor imaging agent is provided. The multivalent glycoligand-DTPA derivatives (In-111-DTPA-hexa lactoside and In-111-DTPA-tri-galactosamine glycoside) labeled with In-111 are used as hepatic receptor imaging agent. The effects of imaging of a hepatic receptor in different species are evaluated, the lowest specific radioactivity... Agent: Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan

20110097269 - Phenyloxyaniline derivatives: The present invention relates to phenyloxyaniline derivatives, to methods of their production and to uses thereof.... Agent:

20110097268 - Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers: We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells.... Agent: Board Of Regents, The University Of Texas System

20110097271 - Colon cancer associated transcript 1 (ccat1) as a cancer marker: The present invention relates to the identification, isolation, and sequencing of a unique nucleic acid transcript termed Colon Cancer Associated Transcript 1 (CCAT-1) that is specifically expressed in cancer cells, in particular in colon, rectal, and lung cancer, as well as in precancerous lesions. The present invention thus provides methods... Agent: Ludwig Institute For Cancer Research And Cancer In

20110097272 - Method and materials for use in diagnosing viral myocarditis: The invention consists of assay methods, assay kits and antibodies for detecting the polypeptide fragments of dystrophin protein cleavage by enteroviral protease 2A as a result of an enteroviral infection in the heart. The presence of dystrophin cleavage products in the myocytes or blood of a subject is diagnostic for... Agent: The Regents Of The University Of California

20110097270 - Monoclonal antibodies that bind or neutralize hepatitis b virus: The present invention relates to the isolation and characterization of a novel neutralizing chimpanzee monoclonal antibody to hepatitis B virus. The invention provides such antibodies, fragments of such antibodies retaining hepatitis B virus-binding ability, fully human or humanized antibodies retaining hepatitis B virus-binding ability, and pharmaceutical compositions including such antibodies.... Agent:

20110097273 - Spectral imaging: A method includes concurrently modulating administration of at least two different contrast agents to a subject during an imaging procedure based on a modulation profile. The at least two different contrast agents exhibit different spectral characteristics. The method further includes performing a spectral decomposition of data indicative of the at... Agent: Koninklijke Philips Electronics N.v.

20110097274 - Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (pet) imaging for the brain serotonin transporters: This invention also provides for related compounds and pharmaceutical compositions. This invention further provides for a compound that can be used for non-invasive method for positron emission tomography (PET) imaging of serotonin transporter sites in mammals comprising labeling serotonin transporter sites (SERT) with an image-generating amount of the radiolabeled compound... Agent:

20110097277 - Particles coated with zwitterionic polymers: Nanoparticles zwitterionic polymers grafted thereto or grafted therefrom, and methods for making and using the nanoparticles. Zwitterionic nanogels, and methods for making and using the nanogels.... Agent: University Of Washington

20110097276 - Diagnosis of prostate cancer: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies,... Agent:

20110097275 - Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy: The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with... Agent: Bracco Suisse Sa

20110097278 - Hair styling compositions and methods of use: Provided is a hair-styling composition, which preferably includes a poly(vinylamine-vinylformamide) copolymer, a polyvinylpyrrolidone, and water, wherein the composition when applied to human hair, exhibits at least about 50% curl retention after about 2 hours under conditions of about 90% relative humidity and about 75° F. Also provided are methods for... Agent: Alberto-culver Company

20110097280 - Intracorporeal medicaments for photodynamic treatment of disease: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used... Agent: Provectus Pharmatech, Inc.

20110097279 - Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses: A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.5% to about 15% by weight; water; an effective amount of an active pharmaceutical agent having a degree... Agent: Foamix Ltd.

20110097281 - Foam skin care cream: The present invention relates to a formulation comprising an aqueous emulsion and a blowing agent for a foaming skin cream, a distinctive feature thereof being that the emulsion comprises microsilver.... Agent:

20110097282 - New use for budesonide and formoterol: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.... Agent: Astrazeneca Ab

20110097283 - Chewing gum compositions comprising cannabinoids: The present invention relates to a chewing gum composition comprising 0.01 to 15% by weight a cannabinoid or a derivative thereof, based on the total weight of the chewing gum composition, and to chewing gums and blistering packages comprising said chewing gums.... Agent: Mareda Holding Bv

20110097284 - Use and methods for preventing and/or treating oral malodour: Described is a microorganism belonging to the group of lactic acid bacteria which is able to drastically reduce the peptide concentration in saliva thereby depleting the substrate used by anaerobic microorganisms of the oral micro-flora which are the causative agent for oral malodour. Moreover, described is a microorganism belonging to... Agent: Basf Se

20110097285 - Multiplex dentifrice compositions: This invention provides a novel aqueous dentifrice composition having multiplex effects on desulfurization of teeth, oral tissue, and on other dental and oral/body care and treatments. The dentifrice composition combined with electromagnetic energy and/or with treatment substances provides advanced means for daily oral/body care and treatments.... Agent: American Environmental Systems, Inc.

20110097286 - Compositions and methods for inhibiting par2 activation of keratinocytes: A composition for inhibiting PAR2 activation of keratinocytes is disclosed as comprising a vitamin B3 compound, an N-acyl amino acid compound, and a Laminaria Saccharina extract. In one embodiment, the composition for inhibiting PAR2 activation of keratinocytes comprises niacinamide, N-undecylenoyl-L-phenylalanine, and a Laminaria Saccharina extract. In response to the technical... Agent:

20110097287 - Cosmetic composition comprising a cationic surfactant compound, novel compounds, use as conditioner and cosmetic treatment method: The present patent application relates to cosmetic compositions comprising cationic compounds of quaternary ammonium esters derived from 2-[2-(diethylamino)ethoxy]ethanol type, to the use of these cationic compounds, in particular as conditioning agent, to a cosmetic treatment method, in particular a hair treatment method, employing them and to the novel cationic compounds.... Agent: L'oreal

20110097288 - Sun protection composition: Cosmetic compositions with improved shelf stability for sun protecting factor. The compositions contain the UV filters 4-(tert-butyl)-4′-methoxydibenzoylmethane, Polysilicone-15, 2-cyano-3,3-phenylcinnamic acid 2-ethylhexyl ester, and at least one water-soluble UV filter, as well as at least one neutralization agent for the water-soluble UV filter, as well as at least one salt of... Agent:

20110097289 - Decorative cosmetic compositions: The invention relates to decorative cosmetic compositions containing specific polyurethanes or aqueous dispersions thereof and constituents producing decorative effects.... Agent: Bayer Materialscience Ag

20110097290 - Cosmetic composition comprising siliconed sapucainha ester and a cosmetic product comprising said composition: e

20110097291 - Fruity odorant: The present invention concerns the use as perfuming ingredient (of the fruity type) of a compound of formula (I) in the form of any one of its stereoisomers or of a mixture thereof, and wherein R1 represents a C1-3 alkyl or alkenyl group, R2 represents a methyl or ethyl group,... Agent: Firmenich Sa

20110097292 - Human sebum mimetics derived from botanical sources and methods for making the same: Human sebum mimetics and methods for producing human sebum mimetics are provided. In one exemplary embodiment, a human sebum mimetic comprises a wax ester derived from interesterification of refined botanical oil comprising palmitoleic acid and refined jojoba oil, a phytosterol, and phytosqualene. A method for producing a human sebum mimetic... Agent: International Flora Technologies Ltd.

20110097294 - Highly foaming composition: The invention relates to high foaming composition comprising a surfactant, and an agent enhancing foaming properties. The agent is a random copolymer comprising cationic units.... Agent:

20110097293 - Multiple component systems and methods for hair relaxation of variable strength: Systems and related methods for straightening or relaxing human hair. The components of the systems and methods include a formulated relaxer cream or relaxer precursor cream that contains a level of alkali metal hydroxide or alkali earth metal hydroxide and an additional diluent cream of similar viscosity and consistency, yet... Agent:

20110097295 - Composition for tissue preservation: The present invention relates to the use of a composition comprising 2-bromo-2-nitropropane-1,3-diol for tissue preservation and more particularly for the preservation of bodies and anatomical parts or for carrying out embalming procedures.... Agent:

20110097296 - Novel pyran derivatives, their preparation and use thereof in perfumery: A process of preparing a compound of formula (I) wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavouring composition.... Agent:

20110097297 - Isomers of bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester and their use in perfume compositions: p

20110097298 - Skin preparation for external use: The present invention provides an external composition for skin that has excellent effects in improving elasticity and alleviating wrinkles while moisturizing the skin, has good spreadability on the skin, and has no stickiness. The external composition for skin of the present invention is characterized by comprising: (A) an acrylic polymer... Agent: Shiseido Co., Ltd.

20110097299 - Swellable and degradable microspheres: Swellable and degradable microspheres are described. The microspheres are prepared by a process that is reliable and high yielding, and makes use of a low temperature azo initiator, a small molecule chlorinated solvent as the organic phase, and a heat treatment step, and is carried out in absence of a... Agent: E.i. Du Pont De Nemours And Company

20110097301 - Angiogenesis promoted by caged growth factors: The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates... Agent:

20110097300 - Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis: The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those... Agent:

20110097304 - Compositions and methods for reducing the likelihood of spontaneous abortion in recipients of artifical insemination: Methods and kits for preventing or reducing the likelihood of spontaneous abortion in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).... Agent: Nora Therapeutics, Inc.

20110097302 - Il-1ra-polymer conjugates: This invention relates to protein-polymer conjugates described in the specification. Also disclosed are a method for preparing a protein-polymer conjugate and using such a conjugate in treating various immune disorders.... Agent:

20110097303 - Methods and compositions for treating and preventing viral infections: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving... Agent:

20110097305 - Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-me-dialed disorders, such as cancer. The subject compounds arc gem-disubstituted or spimcyclic pyridine, pyrimidine and triazine derivatives.... Agent: Amgen Inc.

20110097306 - Oral formulations of cladribine: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.... Agent: Ares Trading S.a.

20110097307 - Compositions and methods for augmenting kidney function: The present invention provides a nutritional food product composed of a prebiotic and an isolated protein for use in reducing elevated levels of nitrogenous waste products in the blood and ameliorating renal failure.... Agent: Kibow Biotech Inc.

20110097311 - Composition having biocide activity for aqueous preparations: The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations.... Agent:

20110097310 - Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng: The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of Panax ginseng, including wild ginseng and ginseng, or an extract thereof, a lysate thereof and a culture thereof. The composition has minimized side effects... Agent: Unhwa Corporation

20110097309 - Pharmaceutical agent for promoting the functional regeneration of damaged tissue: e

20110097308 - Stem cells treated by in vitro fucosylation and methods of use: A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other... Agent:

20110097312 - Anti-cancer vaccines: The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions... Agent: Board Of Regents, The University Of Texas System

20110097314 - Method for producing a composition for promoting survival of transplanted hematopoietic stem cell: HLA matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA matched activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely... Agent: Lymphotec Inc.

20110097313 - Method for the identification and separation of non-regulatory t-cells from a mixture of regulatory t-cells: The present invention relates to a method of identifying and separating non-regulatory T-cells (conventional T-cells) from a mixture comprising regulatory T-cells by using of the CD154 molecule (CD40 ligand) through depletion of CD154+ T-cells from the mixture or in combination with additional positive selection of Treg using markers that are... Agent: Miltenyi Biotec Gmbh

20110097315 - Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-43-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically... Agent:

20110097316 - Composition to be absorbed through mucous tissue: The invention relates to a composition to be absorbed via mucous tissue, containing at least one hormone cleavable by proteinases and at least one proteinase or mixture of proteinases, where the at least one hormone is kept separate from the proteinase or mixture of proteinases in the composition, and furthermore... Agent:

20110097319 - Antibody capable of binding specifically to ab-oligomer, and use thereof: The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.... Agent: National Center For Geriatrics And Gerontology

20110097318 - Solid-state protein formulation: Provided are systems comprising delivery vehicles for the stable storage of immobilized proteins, e.g., protein therapeutics, in a form amenable to administration, such as by injection or infusion, in combination with an elution fluid. Also provided are proteins adsorbed to chromatography media in a form compatible with a one-step administration... Agent: Amgen Inc.

20110097317 - Thioredoxin interacting protein (txnip) as regulator of vascular function: The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or... Agent: University Of Rochester

20110097320 - 4-aminoquinazoline derivatives and methods of use thereof: This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and... Agent: Concert Pharmaceuticals Inc.

20110097321 - Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the... Agent: Astrazeneca Ab

20110097323 - Her2/neu-specific antibodies and methods of using same: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such... Agent: Macrogenics, Inc.

20110097322 - Partially loaded antibodies and methods of their conjugation: A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating... Agent: Seattle Genetics, Inc.

20110097324 - Compositions and methods for modulating nicotinic/nmda receptor function: The present invention provides a method for modulating nicotinic/NMDA receptor function in a mammal in need of such treatment comprising administering a therapeutically effective amount of an agent that disrupts heterodimerization of α7 neuronal nicotinic acetylcholine receptors and N-methyl-D-asparate glutamate receptor. A polypeptide and fragments thereof comprising an amino acid... Agent: Centre For Addiction And Mental Health

20110097326 - Anti-trkb antibodies: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.... Agent: Irm LLC

20110097325 - Modulation of t cell differentiation for the treatment of t helper cell mediated diseases: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype... Agent: Genentech, Inc.

20110097327 - Product and method for treatment of conditions associated with receptor-desensitization: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and... Agent: National Jewish Health

20110097329 - Compositions and methods for treating cancer and modulating stress granule formation: The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also... Agent: Massachusetts Institute Of Technology

20110097328 - Methods and compositions for increasing the activity of inhibitory rna: The invention provides methods for increasing the activity of an inhibitory RNA (RNAi) in a subject requiring administering one or more poly-ADP-ribose polymerase (PARP) inhibitors and/or one or more PARG activators to the subject. The invention also provides methods for increasing the activity of an inhibitory RNA in a cell... Agent: Massachusetts Institute Of Technology

20110097331 - Antibodies that bind both il-17a and il-17f and methods of using the same: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same... Agent: Zymogenetics, Inc.

20110097332 - Composition and method of use for hcv immunization: Isolated HCY E2 kinase phospho-peptides that contain one or more immunogenic fragments of a HCV E2 kinase motif and antibodies which are cross-reactive with the isolated HCV E2 kinase phospho-peptides are provided. Also disclosed are pharmaceutical compositions and/or methods to passively and/or actively immunize against HCV using the isolated HCY... Agent:

20110097330 - Novel gene disruptions, compostitions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100,... Agent: Lexicon Pharmaceuticals, Inc.

20110097333 - Therapeutic and diagnostic agents: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter... Agent: Th Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland

20110097335 - Abc transporter protein expression inhibitor: e

20110097334 - Novel marker genes for regulatory t cells from human blood: The present invention provides novel marker genes for the specific identification and characterization of human suppressive and/or regulatory T cells including natural, adaptive, and expanded CD4+CD25+FOXP3+ T cells in healthy individuals as well as tumor patients or patients with autoimmune diseases.... Agent: Becton Dickinson And Company

20110097336 - Methods for modulating mannose content of recombinant proteins: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.... Agent: Amgen Inc.

20110097337 - Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells: The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope,... Agent:

20110097338 - Use of substances for sensitization of tumor cells to radiation and/or chemotherapy: The invention relates to the use of substances to increase the sensitivity of tumor cells to treatment with radiation and/or chemotherapy. This is accomplished through the use of substances which block or limit the function of the PINCH-1 protein for sensitization of tumor cells to radiation and/or chemotherapy.... Agent: Technische Universitaet Dresden

20110097339 - Compositions monovalent for cd28 binding and methods of use: The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody... Agent: Domantis Limited

20110097340 - Fully human anti-vegf antibodies and methods of using: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in... Agent:

20110097341 - Treatment of chronic prostatitis: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with chronic prostatitis and/or chronic pelvic pain syndrome.... Agent: Pfizer Inc.

20110097342 - Binding agents: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Ucb Pharma S.a.

20110097343 - Diagnosis and therapy of hematological malignancies: The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were... Agent:

20110097344 - Compositions, methods for treatment, and diagnoses of autoimmunity-related disorders and methods for making such compositions: The present invention provides compositions and methods useful in the diagnosis and treatment of autoimmunity-related disorders, including cancers and other disorders involving angiogenesis, as well as non-cancer disorders involving a dysfunction in the immune system. In some embodiments, the invention described a plasma assay. In other embodiments, urine assay. In... Agent: Eiger Health Partners, LLC.

20110097345 - Novel dosing regimen and method of treatment: This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min... Agent: Immunogen Inc.

20110097346 - Dendritic cells: The present invention relates to dendritic cell loaded with at least one nucleic acid molecule encoding a tumor associated antigen protein or fragment thereof and at least one tumor associated antigen protein or fragment thereof.... Agent: Cell Med Research Gmbh

20110097350 - Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same... Agent: Vascular Biogenics Ltd.

20110097347 - Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad): The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising... Agent:

20110097349 - Phosphoinositide 3-kinase inhibitor compounds and methods of use: Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders... Agent:

20110097348 - Protein formulation: A composition comprises a biological molecule that is susceptible to aggregation, dimerisation or hydrolysis, wherein the ionic strength is less than 40 mM.... Agent: Arecor Limited

20110097351 - Compounds for treating beta-amyloidoses: The present invention relates to the use of mimotopes in the treatment of diseases associated with β-amyloid formation and/or aggregation (β-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to Aβ1-40/42, AβpE3-40/42, Aβ3-40/42 and Aβ11-40/42.... Agent: Affiris Ag

20110097352 - Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.... Agent: Pharmexa Inc.

20110097353 - Poultry viral materials and methods related thereto: The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids,... Agent:

20110097354 - System for the expression of peptides on the bacterial surface: Expression system of peptides on the bacterial surface characterised in that membrane-binding region the conserved sequence of the MSP1a protein of Anaplasma marginale.... Agent: Universidad De Castilla La Mancha

20110097355 - Virus-like particles as vaccines for paramyxovirus: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an... Agent:

20110097356 - Anti-inflammatory and antioxidant cosmetic composition containing green tea polysaccharide and tricholoma matsutake extract: Disclosed herein is a cosmetic composition which can inhibit skin aging resulting from external harmful environmental factors such as UV light and environmental pollution, which promote aging. More specifically, disclosed is a cosmetic composition, which contains green tea polysaccharide and Tricholoma matsutake extract and shows an excellent anti-aging effect by... Agent:

20110097357 - Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells: The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one... Agent: Glycovaxyn Ag

20110097358 - Respiratory syncytial virus (rsv) virus-like particles (vlps): Respiratory syncytial virus (RSV) virus-like particles (VLPs) comprising at least one RSV protein are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs.... Agent: Techno Vax, Inc.

20110097359 - Production of diphtheria toxin: A Corynebacterium diphtheriae culture medium for the production of diphtheria toxin and methods for producing the toxin are provided. The medium is substantially free of animal-derived products and comprises water, a carbohydrate source, a nitrogen source and a number of free amino acids in an initial concentration wherein the initial... Agent:

20110097360 - Streptococcus pneumoniae pilus antigens: Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INV1 04B)) identified in Streptococcus pneumoniae isolate INV1 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141... Agent:

20110097361 - Method of inducing tolerance to an allergen: The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also... Agent:

20110097364 - Macrocyclic lactone compounds and methods for their use: e

20110097363 - Therapeutically effective preparations of insulin: The present invention provides a preparation of a therapeutically effective amount of insulin with a concentration of A21 desamido insulin greater than about 2% (w/w).... Agent: Cpex Pharmaceuticals, Inc.

20110097362 - Transmucosal administration of aggregated antigens: The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The invention sets forth methods and compositions useful in inducing oral tolerance and systemic immunity in a mammal.... Agent:

20110097366 - Goniochromatic/light reflective cosmetic makeup compositions: Goniochromatic/light reflecting cosmetic compositions well suited for making up the skin, lips, hair or integuments, contain (a) at least one goniochromatic coloring agent and (b) an amount of light reflective particles different from said at least one goniochromatic coloring agent and selected from the group consisting of (i) particles of... Agent: Societe L'oreal, S.a.

20110097367 - Monolithic in-situ cross-linked alginate implants: A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting the alginate solution into a patient at a predetermined site to form a gel body comprising the monolithic alginate implant.... Agent: Cellmed Ag

20110097369 - Particulate detergent additive: Laundry-detergent and cleaning-product additives in particle form, comprising a water-soluble or water-dispersible carrier and active ingredient microcapsules. These particles allow a user to obtain particular advantages with respect to fragrancing and care of the articles treated in conventional laundering and cleaning operations, such as, in particular, in automatic laundering of... Agent:

20110097365 - S-triazine derivatives containing at least two particular silane aminobenzoate or silane aminobenzamide groups; photoprotective cosmetic compositions containing these derivatives; uses of the said s-triazine derivatives: The invention relates to novel s-triazine derivatives containing at least two particular silane aminobenzoate or silane aminobenzamide groups and to their cosmetic uses. The invention also relates to photoprotective compositions comprising s-triazine derivatives containing at least two particular grafted silane aminobenzoate or silane aminobenzamide groups as sunscreens that are active... Agent: L'oreal

20110097368 - Treatment varnish compositions for teeth surfaces: Embodiments of the present invention include compositions, methods, and systems for providing an effective and efficient treatment varnish for teeth. For example, embodiments of the present invention provide a treatment varnish that comprises one or more polymers and/or copolymers that are soluble in biocompatible solvents, such as ethanol. The polymers... Agent: Cao Group, Inc.

20110097370 - Antimicrobial composition, antimicrobial brush filaments and preparation method thereof: Disclosed is a method for preparing an antimicrobial composition for making filament for brushes. The method comprises steps in the following order: (1) mechanically pulverizing a polymer to obtain a polymer powder; (2) blending the polymer powder obtained in step (1) with an antimicrobial agent comprising phosphate, or glass, micropowder... Agent: E. I. Du Pont De Nemours And Company Dupont Xingda Filaments Company Limited

20110097371 - Process of making a stable aqueous dispersion of concentrated, finely divided particles of a biocide: This invention provides a process of making a stable aqueous dispersion including concentrated, finely divided particles of a water insoluble biocide active, which comprises grinding the biocide in water in the presence of a non-ionic polymeric dispersant and optionally a co-dispersant, and compositions prepared by this process.... Agent:

20110097373 - Bone prosthetic material and method of manufacturing the same: A method of manufacturing a bone prosthetic material, includes by forming tricalcium phosphate (TCP) particle precursor particles; by performing preliminary sintering on the TCP precursor particles at a temperature in a first temperature range to produce TCP particles of diameters in a predetermined diameter range; by granulating the TCP particles... Agent: Brain Base Corporation

20110097372 - Devices, methods, and compositions for controlling infections: The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation.... Agent:

20110097378 - Decellularized liver for repair of tissue and treatment of organ deficiency: The present invention provides a liver-derived devitalized mammalian parenchymatous tissue composition which includes an interstitial structure of connective tissue which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.... Agent:

20110097379 - Directed stem cell recruitment: The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or... Agent: Wake Forest University Health Sciences

20110097375 - Formulation for preventing or reducing bleeding at a surgical site: An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is... Agent: Warsaw Orthopedic, Inc.

20110097374 - Methods and devices for correcting spinal deformity with pharmaceutical-eluting pedicle screws: A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. The screw... Agent:

20110097377 - Methods and devices for correcting spinal deformity with pharmaceutical-eluting pedicle screws: A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. In some... Agent:

20110097376 - Radiopaque injectable nucleus hydrogel compositions: m

20110097380 - Clonidine formulations having antimicrobial properties: Antimicrobial clonidine compositions are provided. These antimicrobial clonidine compositions can be applied to medical devices or be part of a drug depot. Through the administration of an effective amount of clonidine at or near a target site, one can reduce, prevent, or treat infections. When appropriate clonidine compositions are provided... Agent: Warsaw Orthopedic, Inc.

20110097381 - Conformable tissue repair implant capable of injection delivery: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or... Agent: Depuy Mitek, Inc.

20110097382 - Methods and kits for reducing the likelihood of implantation failure and pregnancy-related disorders in recipients of artificial insemination: Methods and kits for preventing or reducing the likelihood of implantation failure and pregnancy-related disorders in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).... Agent: Nora Therapeutics, Inc.

20110097383 - Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome: Apparatus suitable for use in the prevention and treatment of burn induced compartment syndrome facilitates the rapid and efficient deployment of enzymatic compositions to the affected limb or limbs of a burn victim suffering from a circumferential burn. The apparatus includes a flexible, water-impermeable generally cylindrical covering layer. The covering... Agent:

20110097384 - Transdermal drug delivery device including an occlusive backing: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the... Agent: Noven Pharmaceuticals, Inc.

20110097392 - Antibody bound synthetic vesicle containing molecules for deliver to central and peripheral nervous system cells: A process is provided of delivering at least one active agent cargo molecule into an neuronal cell whereby a cargo molecule is placed within a synthetic vesicle such as a liposome and a biotinylated protein such as an antibody is bound to the synthetic vesicle to form a protein bound... Agent: Banyan Biomarkers, Inc

20110097385 - Delivery system for drug and cell therapy: A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for... Agent: Ttdc Bio L.p.

20110097388 - Methods of expressing proteins with disulfide bridges: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The... Agent: University Of Southern California

20110097389 - P53 biomarkers: The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.... Agent: P53

20110097387 - Particulate drug carriers as desensitizing agents: The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.... Agent:

20110097391 - Phospholipid emulsion containing dihydroquercetin, and method of producing thereof: This present invention relates generally to the field of chemistry, food industry, cosmetics, and pharmaceutical industry. More specifically, the present invention relates to liposomal biologically active forms and methods of producing thereof. The present invention provides a stable phospholipid emulsion based on dihydroquercetin (DHQ), its compounds and derivatives. The invention... Agent: Obschestvo S Ogranichennoi Otvetstvennostju Scientific Company Flamena

20110097393 - Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery: This invention relates to a sustained release oral and transdermal pharmaceutical formulations and delivery systems comprising lofexidine. The invention is also directed to methods of treatment comprising administering lofexidine in a sustained release manner. Such methods can involve administration of the lofexidine containing compositions described herein. Compositions of lofexidine formulated... Agent: Us Worldmeade, LLC

20110097386 - Stabilized glucagon solutions: A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so... Agent: Biodel, Inc.

20110097390 - Ultra-small rnas as toll-like receptor-3 antagonists: Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR3. Administration of double stranded RNAs having a length of 22 nucleotides or less treats or prevents macular degeneration or other diseases or disorders associated with activation of... Agent: University Of Kentucky Research Foundation

20110097395 - Oral pharmaceutical compositions of buprenorphine and method of use: The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof.... Agent:

20110097394 - Type a gelatin capsule containing pufa in free acid form: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of... Agent:

20110097396 - Peeling capsule with integrated care effect: A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising... Agent:

20110097397 - Break resistant gel capsule: A gelatin capsule is disclosed that is designed to impart less tensile stress on the component parts when it is in the closed position and experiences less spontaneous breakage particularly when fill with hygroscopic liquids. The gelatin capsule comprises a cap portion and a body portion. The cap portion includes... Agent: Patheon Pharmaceuticals

20110097398 - Reduction of cross-linking gelatin in gelatin capsules: The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication... Agent:

20110097399 - Fast dissolving/disintegrating coating compositions: A pharmaceutical composition for oral administration comprising a core and a film coating on the core that exhibits enhanced disintegration characteristics is disclosed. The film coating comprises a film forming polymer, an organic solvent, a super-disintegrant and, optionally, an acid labile material.... Agent:

20110097400 - Magnesium system and use thereof in the cosmetics industry: A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a rate of dissolution (δ) of the magnesium contained therein of less than or equal to 60% by... Agent:

20110097401 - Methods for treating gastrointestinal disorders: Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.... Agent: Meritage Pharma, Inc.

20110097403 - Extracellular matrix compositions for the treatment of cancer: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a... Agent: Histogen, Inc.

20110097402 - Non-adhesive elastic gelatin matrices: The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making... Agent: Covalon Technologies Inc.

20110097404 - Tamper-resistant oral opioid agonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.... Agent: Purdue Pharma L.p.

20110097405 - Estradiol-containing drug delivery system: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels... Agent: Bayer Schering Pharma Aktiengesellschaft

20110097407 - Butenafine hydrochloride-containing aqueous patch: Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which... Agent: Teikoku Seiyaku Co., Ltd.

20110097406 - Methods and compositions for retaining ecm materials in hydrogels: The present invention provides cell-laden and/or extracellular matrix material laden hydrogels for use in tissue engineering and methods for producing such hydrogels. In some particular embodiments, hydrogels comprise chondrocytes, which are typically encapsulated within the hydrogels. In many instances, such hydrogels are subjected to dynamic loading prior to being administered... Agent: The Regents Of The University Of Colorado, A Body Corporate

20110097408 - Chitosan-based matrices and uses thereof: This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology... Agent:

20110097411 - Carrier pellets, method for production thereof and use thereof: The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in... Agent: Add Technologies Ltd.

20110097410 - Formulations of px compounds: Nanoparticles of PX compounds in the size range of 10 to 1000 nanometers are incorporated into formulations that are safe for intravenous administration and used to treat disease conditions caused by phospholipase A2 (PLA2) such as ischemia-reperfusion injury.... Agent:

20110097412 - Methods of treatment of endobronchial infections: The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period... Agent:

20110097409 - Particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone having improved adhesion properties for powder formulations for inhalation: Powder particles comprising a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol) having a specific properties exhibit improved adhesion properties for dry powder formulations for inhalation. Such particles are useful for formulations in the form of powders for inhalation and the treatment of certain conditions and diseases.... Agent: Chiesi Farmaceutici S.p.a.

20110097413 - Solid state forms of deferasirox salts and process for the preparation thereof: Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (I) in high purity.... Agent: Actavis Group Ptc Ehf

20110097414 - Pharmaceutical compositions comprising adsorbate of fenofibrate: The present invention provides a pharmaceutical composition comprising adsorbate of fenofibrate or salt thereof or fenofibrate adsorbed on a pharmaceutically acceptable adsorbent and optionally one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions.... Agent:

20110097415 - Sustained release of pharmaceutical composition containing a safe botanic drug for the treating and preventing of diabetes: e

20110097416 - Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles: Provided herein are systems, methods, and compositions for polymer nanoparticles and polymer magnetic nanoparticles. More particularly, the polymer nanoparticles and polymer magnetic nanoparticles are temperature sensitive and responsive to a first temperature.... Agent: Board Of Regents, The University Of Texas System

20110097418 - Compositions and methods for treating influenza: The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g.,... Agent: Variation Biotechnologies, Inc.

20110097417 - Melan-a-carrier conjugates: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA... Agent: Cytos Biotechnology Ag

20110097420 - Cement products and methods of making and using the same: Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more... Agent: Angstrom Medica

20110097419 - Poly(propargyl-l-glutamate) and derivatives thereof: A process of the present invention is directed toward conducting highly selective, high yield post-polymerization reactions on polypeptides to prepare functionalized polypeptides. In certain embodiments, the polypeptides can be prepared by ring opening polymerization of N-carboxyanhydrides. In certain embodiments, the post-polymerization reaction is a “click chemistry” reaction. In certain embodiment,... Agent: Massachusetts Institute Of Technology

20110097421 - Method for the cosmetic treatment of skin ageing: The present invention relates to a method for the cosmetic prevention or treatment of skin ageing in an individual, comprising administering to said individual a cosmetically active quantity of a gingival fibroblast-derived product.... Agent:

20110097422 - Cleaning, disinfecting and microbicidal compositions: A microbicidal disinfecting composition and a method of preparing the same include the use of an acidifying agent that comprises at least one of an alkali metal bisulfate, ammonium bisulfate, or a combination thereof. The composition has broad-spectrum microbicidal properties and does not demonstrate cloudiness or precipitation when prepared, diluted,... Agent:

20110097423 - Gene prognosis predictor signature for colorectal carcinoma: The present invention is drawn to methods of assessing colorectal cancer prognosis by examining the expression of particular genes disregulated in this disease state. Subjects exhibiting disregulation in one or more of these genes will have a higher risk of cancer recurrence and death.... Agent: Vanderbilt University

20110097424 - Herbal formulations for the management of chronic ulcers and wounds: The invention describes ointments, creams and oils formulated from herbal compositions that are suitable for the management of skin wounds, such as chronic skin ulcers, as, for example, diabetic ulcers and pressure ulcers, and for providing bleeding control for cuts and wounds. The compositions contain extracts of two or more... Agent: Apptec Inc.

20110097425 - Methods of treating epiphora: The present invention is related to a method for treating epiphora, the method comprising administering to a nasal area of a subject in need thereof a composition comprising camphor, eucalyptus oil, and menthol, wherein the composition is substantially free of lipids other than the eucalyptus oil.... Agent:

20110097426 - Methods for safe and effective treatment using oxazaphosphorine drugs: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.... Agent: Accentia Biopharmaceuticals, Inc.

20110097427 - Molecular targets and dietary modulators of exercise-induced muscle damage: Dietary supplement compositions include an adaptogenic agent, an anti-inflammation agent, and an anti-oxidant. Methods for using dietary supplement compositions include (i) inhibiting, decreasing, and/or preventing delayed onset of muscle soreness (DOMS); (ii) inhibiting, decreasing, and/or preventing exercise-induced muscle damage; and/or (iii) modulating the expression of genes that are correlated with... Agent:

20110097428 - Blended compositions for treatment of alzheimer's disease and other amyloidoses: Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and Grape Seed Extract.... Agent:

20110097429 - Use of vernonia extract: The present invention relates to the use of an extract of a Vernonia plant from Madagascar in cosmetics, pharmaceuticals and food supplements for improving the skin status, more specifically by strengthening the dermal-epidermal junction and/or by activating fibroblasts synthesis of dermis and extracellular matrix compounds.... Agent:

20110091374 - Contrast agents for applications including perfusion imaging: The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.... Agent: Lantheus Medical Imaging, Inc.

20110091372 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Laboratories

20110091373 - Paa nanoparticles for enhancement of tumor imaging: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same.... Agent: Regents Of The University Of Michigan

20110091375 - Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma: Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNFα, or with temozolomide, TNFα, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNFα, or with temozolomide, TNFα,... Agent: Dana-farber Cancer Institute, Inc.

20110091376 - Catatonic steroid antimicrobial diagnostic, detection, screening and imaging methods: The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in... Agent: Brigham Young University

20110091377 - Biomarkers for melanoma: The present invention relates to methods of determining melanoma status in a subject. The invention also relates to kits for determining melanoma status in a subject. The invention further relates to methods of identifying biomarkers and correlating biomarker expression to melanoma status or stage in a subject.... Agent: The Johns Hopkins University

20110091379 - Method for treating tumors and their metastases: The invention relates to a medicament against tumors and their metastases, which preferentially settle in bone tissue, comprising active ingredient at least one binding molecule that binds to bone sialoprotein or a fragment thereof in serum or plasma.... Agent: Armbruster Biotechnology Gmbh

20110091378 - Methods and compositions for treating fibrosis related disorders using il-17 antagonists: The present invention relates methods and compositions for treating interleukin-17 (IL-17) related conditions, such as IL-17A or IL-17F, or muteins thereof in patients having fibrosis using IL-17 antagonists, such as small molecule IL-17 antagonists or protein IL-17 antagonists, such as antibodies, including specified portions or variants, specific for at least... Agent:

20110091380 - Chlorotoxins as drug carriers: The present invention relates to the use of a toxin moiety (e.g., a chlorotoxin moiety) as a carrier for therapeutic agents, e.g., therapeutic agents that require intracellular uptake to exert their effects. For example, in some embodiments, the present invention provides conjugates comprising a toxin (e.g., a chlorotoxin) moiety and... Agent: Transmolecular, Inc.

20110091381 - Gaba biomarkers for depression: Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset... Agent:

20110091383 - Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents: Synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR) are disclosed, as are their uses as therapeutic, diagnostic and imaging agents for cancer and other diseases.... Agent:

20110091382 - Novel imaging agents for detecting neurological dysfunction: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles... Agent: Siemens Medical Solution Usa, Inc.

20110091384 - Biomarker for identification of melanoma tumor cells: This invention relates to use of neuropilin-2 as a novel biomarker and therapeutic target for melanoma. The presence of neuropilin-2 can be used as a biomarker for diagnosing and detecting individuals suffering from or at risk for developing melanoma. Also described are methods of using neuropilin-2 to capture circulating melanoma... Agent: The Johns Hopkins University

20110091386 - Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell,... Agent: Gene Techno Science Co., Ltd.

20110091385 - Substituted aryl piperidinylalkynyladenosines as a2ar agonists: e

20110091387 - Methods and compositions for reducing skin damage: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced sin... Agent: Shiseido Co., Ltd.

20110091388 - Use of pde7 inhibitors for the treatment of movement disorders: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in... Agent: Omeros Corporation

20110091389 - Particles with radiation activated adhesive: Techniques are generally described for particles with a surface including an adhesion material. The adhesion material may be selectively activated in response to radiation. The particles may be distributed proximate to a target through a fluid system. Radiation may be emitted toward the target causing the adhesion material to activate.... Agent:

20110091390 - Water soluble tetrapyrollic photosensitizers for photodynamic therapy: or a pharmaceutically acceptable derivative thereof, wherein R1—R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection... Agent: Health Research, Inc.

20110091392 - Compositions for the treatment and prevention of infections of the oral cavity: The present invention relates to compositions comprising benzophenanthridine alkaloids, benzofuran compounds and catechin polyphenols, which are useful in the treatment and prevention of infections of the oral cavity.... Agent: Indena S.p.a

20110091391 - Discrete tunable sensing elements and compositions for measuring and reporting status and/or product performance: Discrete sensing elements are described that can be integrated into dental hygiene products and can provide rapid and direct feedback to a user as to oral environmental status and as to the performance of the intended oral care product. Selectively tuned elements can both sense and report relevant information including... Agent:

20110091393 - Exothylate-free personal care cleansing compositions: Provided are personal care cleansing compositions that are substantially ethoxylate free, especially a personal care composition, comprising: hydroxypropyl methyl cellulose having a hydroxypropyl MS of about 0.8 or greater and a methoxyl DS of about 2 or greater; and an alkyl polyglycoside surfactant.... Agent:

20110091394 - High-purity rebaudioside d and low-calorie tooth paste composition containing the same: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The invention further provides a low-calorie tooth paste composition containing the purified Rebaudioside D and a process for... Agent: Purecircle Sdn Bhd

20110091395 - Extract of phaleria macrocarpa as an antineoplastic, anti-inflammatory and antiangiogenic agent: A pharmaceutical dosage form comprising an extract of Phaleria macrocarpa which has antineoplastic, anti-inflammatory, and antiangiogenic activity. Its use as an antineoplastic agent is to inhibit tumour growth. Its use as an anti-inflammatory agent is to relieve inflammation and pain, and also as an antipyretic. Another use is as an... Agent: Pt Dexa Medica

20110091398 - Oleanoyl peptide composition and a method of treating skin aging: The present invention relates to a composition containing peptide of SEQ ID No. 1 linked to oleanolic acid and a method of treating skin aging. The composition effectively reduces signs of ageing due to oxidation, collagen insufficiency and excess activity of serine proteases like elastase and collagenase that result in... Agent:

20110091397 - Stable water-in-oil emulsion system: A water-in-oil emulsion system is provided that includes a water phase, an oil phase, a water-in-oil emulsifier of 1-5 wt % on the basis of the total amount of the system, a solid powder of 0.1-20 wt % on the basis of the total amount of the system and a... Agent: Evonik Goldschmidt Gmbh

20110091396 - Sunless tanning composition insuring effective application to skin: A sunless tanning composition is provided with from 0.1 to 40% of a C1-C24 alpha-hydroxyaldehyde and from 0.1 to 15% of hydrophobic droplets, the droplets including from 80 to 99.9% of a lipophilic substance and from 0.01 to 3% of a particulate colorant dispersed within the lipophilic substance, and wherein... Agent: Conopco, Inc., D/b/a Unilever

20110091399 - Use of organo-modified siloxane block copolymers for producing cosmetic or pharmaceutical compositions: The invention relates to emulsifier systems comprising organomodified siloxane block copolymers, their use, in particular the preparation of cosmetic, dermatological or pharmaceutical formulations, and of care and cleaning compositions, and also the products themselves prepared with the help of emulsifier systems.... Agent: Evonik Goldschmidt Gmbh

20110091400 - Cosmetic emulsifier combination: The invention relates to a cosmetic composition comprising a) sodium stearyl glutamate, b) a crosslinked polymer of vinylpyrrolidone and acrylic acid.... Agent: Beiersdorf Ag

20110091401 - Novel water-resistant sunscreen composition: The present invention is directed to sunscreen composition comprising: (a) at least one oil- and water repellent emulsifier chosen from polyperfluoroethoxymethoxy difluoroethyl PEG phosphate; (b) at least one hydrophobically-modified emulsifier chosen from inulin lauryl carbamate; (c) at least one gelling agent; and (d) sunscreen actives, and wherein the composition is... Agent: L'or&#xc9 Al S.a.

20110091402 - Antiperspirant products and processes for fabricating the same: Antiperspirant products and processes for making them are provided. In one embodiment, an antiperspirant product comprises an active antiperspirant compound and a carrier having a first volatility rate in an air ambient at about 50° C. and 1 atm after a first time period and a second volatility rate in... Agent: The Dial Corporation

20110091403 - Oligosaccharide aldonic acids and their topical use: Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment... Agent:

20110091404 - Compositions comprising fragrance substances and comprising cetyl nonanoate and/or stearyl nonanoate: The invention relates to the use of n-hexadecyl n-nonanoate (CAS number 72934-15-7, hereafter cetyl nonanoate) and n-octadecyl n-nonanoate (CAS number 107647-13-2, hereafter stearyl nonanoate) and to the mixtures thereof (CAS number 878027-13-5) as fixatives for fragrance substances. The invention also relates to specific compositions comprising (A) cetyl nonanoate and/or stearyl... Agent: Symrise Ag

20110091405 - Composition and methods for promoting lush hair growth: Compositions, kits and methods are provided for conditioning, revitalizing, volumizing or increasing the natural pigmentation of the hair, including hair on the scalp, eyelashes, eyebrows, mustache and beard, promoting healthy growth, and treating and preventing loss, thinning or miniaturization of hair due to aging, various genetic, pathological, radiation, chemotherapy, chemical... Agent: Jan Marini Skin Research, Inc.

20110091406 - Composition and method for protecting labile active components during high temperature drying: A composition and method for protecting personal care components, advantageously labile active personal care components, from decomposition during high temperature drying, employing water-soluble hydrolyzed polysaccharide encapsulants. Also disclosed is an additive for a personal care composition comprising a personal care component that is at least partially encapsulated within a hydrolyzed... Agent:

20110091408 - Methods of using fluoroalkyl phosphate compositions: Fluoroalkyl phosphates containing a tertiary carbon and a nonfluorinated chain are useful as surfactants and additives. The f can be used to alter a surface property of a medium and to provide resistance to blocking, open time extension, or oil repellency to a substrate.... Agent: E. I. Du Pont De Nemours And Company

20110091407 - Polymer derived from linear polyethylenimine for gene transfer: The invention relates to a static copolymer of linear polyethylenimine that comprises two monomer units of the following formulas I and II, in which R1 is a hydrogen atom or a C1-C6 alkyl radical, R2 is a hydrogen atom, a C1-C6 alkyl, aryl or aralkyl group, wherein the alkyl group... Agent: Centre National De La Recherche Scientifique (cnrs)

20110091409 - Artificial termite egg having beta-glucosidase as termite egg recognition pheromone, and control of termites using the same: The present invention provides a mimetic egg comprising β-glucosidase, a salt thereof, a biological fragment thereof or a β-glucosidase-related peptide as an egg recognition pheromone in its base material mimicking an egg of a insect pests, particularly a termite, a method for exterminating and controlling insect pests, and a tool... Agent:

20110091410 - Engineered cxcl12 alpha locked dimer polypeptide: The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.... Agent: Medical College Of Wisconsin Research Foundation

20110091415 - Hydroxyethyl starch-containing polypeptide compositions: The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.... Agent: The Regent Of The University Of Colorado

20110091416 - Immunoglobulin fusion proteins: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a... Agent: Postech Academy-industry Foundation Of Pohang University Of Science And Technology ( Postech)

20110091411 - Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1... Agent: Cytos Biotechnology Ag

20110091417 - Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of... Agent:

20110091418 - Methods for treating viral infections using polyamine analogs: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but... Agent: Pathlogica, LLC

20110091412 - Mutant interleukin-2 (il-2) polypeptides: The present invention relates to mutant IL-2 polypeptides that act as receptor antagonists. The mutant IL-2 polypeptides bind CD 25 but do not activate the IL-2 receptor. Also provided are methods of using the mutant IL-2 polypeptides, for example, to treat a patient who has cancer or a viral infection.... Agent: Massachusetts Institute Of Technology

20110091414 - Stabilized compositions of proteins having a free thiol moiety: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.... Agent:

20110091413 - Therapeutic use of interleukin-2 mutants: Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a... Agent: University Of Southern California

20110091419 - Use of pegylated il-10 to treat cancer: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.... Agent: Schering Corporation

20110091420 - Injectable sustained-release pharmaceutical formulation and the preparation method thereof: Disclosed are an injectable sustained-release pharmaceutical formulation and a process for preparing the same. In some embodiments, the formulation comprises an active ingredient in a therapeutically effective amount, an amphipathic molecule, an organic acid and/or a salt thereof which is hardly soluble in water, and an oily solvent. The injectable... Agent: Chengdu Yiping Pharmaceutical Science Development Co., Ltd.

20110091421 - Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases: The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods... Agent:

20110091422 - Use of genetic markers for identifying the response to interferon treatment in multiple sclerosis patients: The present invention relates to the use of genetic markers to identify the response to interferon-beta (IFN-beta) treatment in Multiple Sclerosis (MS) patients as well as a method for treating MS patients and kits for genotyping.... Agent: Merck Serono Sa

20110091423 - Compositions and methods of use of ritonavir for treating hcv: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.... Agent: Abbott Laboratories

20110091424 - Oral dosage composition: The present invention is an oral dosage composition for prevention and treatment of hepatic inflammation such as NASH. The present invention is an oral dosage composition for prevention or treatment of hepatic inflammation, contains the radical scavenging active spirulina powder effective in preventing, ameliorating, and curing NASH or the like.... Agent:

20110091425 - Upregulation of opioid receptors for management: Disclosed are methods for treating pain in a subject. The method includes upregulating expression of opioid receptors in the subject's dorsal root ganglion or trigeminal neurons. Also disclosed are methods of treating neuropathic and/or chronic pain in a subject. The method includes upregulating expression of μ-opioid or δ-opioid receptors in... Agent:

20110091430 - Mesenchymal stem cells and methods of use thereof: The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem... Agent:

20110091431 - Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease: Compositions, methods, etc., comprising Pediococcus and at least one other probiotic microbial organism that reduce one or more symptoms of an autism spectrum disorder such as autism. The compositions can be used, for example, as dietary supplements, food additives, and pharmaceutical preparations.... Agent: Prothera, Inc.

20110091432 - Isolated pediococcus acidilactici 05b0111 and method of producing exopolysaccharide: Disclosed herein is an isolated Pediococcus acidilactici 05B0111 capable of producing an exopolysaccharide. The Pediococcus acidilactici 05B0111 is deposited in Biosource Collection and Research Center (BCRC) of Food Industry Research and Development Institute (FIRDI) under an accession number BCRC 910420 and deposited in Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH... Agent: Food Industry Research And Development Institute

20110091428 - Compositions of adult organ stem cells and uses thereof: Compositions of isolated adult organ stem cells, including hematopoietic stem cells, cardiac stem cells, and kidney stem cells, are disclosed. In particular, the present invention provides c-kit positive, lineage negative adult stem cells that can be isolated from adult organ tissue. Such stem cells are capable of generating all the... Agent: New York Medical College

20110091426 - Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells: A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34+CD38− cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34+... Agent:

20110091429 - Methods for enhancing stem cell engraftment during transplantation: The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.... Agent:

20110091427 - Methods for treating a kidney injury: Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney... Agent: Baxter Healthcare S.a.

20110091434 - Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase: Disclosed are methods, compositions of matter, and kits useful for augmentation of homing and engraftment of stem, progenitor and mature cells through modification of cellular membrane properties following ex vivo treatment. The methods, compositions, and cells may be used for the treatment of a wide variety of disorders in which... Agent: America Stem Cell, Inc.

20110091433 - Treatment using reprogrammed mature adult cells: A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments,... Agent:

20110091435 - Phytoestrogenic formulations for alleviation or prevention of hair loss: Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference... Agent: University Of Southern California

20110091436 - Use of matrix metalloproteinase-10 (mmp-10) for thrombolytic treatments: The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.... Agent:

20110091437 - Fusion proteins: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the... Agent: Allergan, Inc.

20110091438 - Radioprotective sod soluble isoform and uses thereof: The invention refers to a specific isoform of MnSOD (Mn-superoxide dismutase) and its uses for protecting and curing subjects exposed to radiations, specifically space radiations.... Agent: Asi Agenzia Spaziale Italiana

20110091439 - Cosmetic use of acid ceramidase type proteins: A method for preventing and/or treating the signs of skin aging comprises administering as an agent into an individual in need thereof an effective amount of acid ceramidase, polypeptides derived from this protein or analogues thereof, a nucleic sequence encoding such a polypeptide, or an agent for modulating the expression... Agent: L'oreal

20110091440 - Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases: A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, as well as neuro-degenerative diseases and protein aggregation diseases, includes an effective amount of a compound selected from the group consisting of phytic acid (inositol... Agent:

20110091441 - Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof: An I-CreI variant, wherein at least one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a... Agent: Cellectis

20110091442 - Novel compositions for preventing and/or treating lysosomal storage disorders: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.... Agent: Amicus Therapeutics, Inc.

20110091443 - Heparin-conjugated fibrin gel and method and kit for preparing same: A method of preparing a heparin-conjugated fibrin gel is provided, which includes activating heparin, conjugating the activated heparin with fibrinogen to prepare heparin-conjugated fibrinogen, mixing free fibrinogen with the heparin-conjugated fibrinogen to prepare a fibrinogen mixture, and mixing thrombin with the fibrinogen mixture. In addition, a heparin-conjugated fibrin gel prepared... Agent: Industry-university Cooperation Foundation Hanyang University

20110091447 - Lymphocyte control of obesity and insulin resistance: Methods for the treatment, inhibition, prevention, etc. of metabolic syndrome (MetSyn) and/or Type-2 diabetes (T2D) using a T cell activating antibody that stimulates activation and immunomodulation of T-cells to affect the immune environment of adipose tissue and improve insulin sensitivity. Also methods for the treatment, inhibition, prevention, amelioration, reversal, etc.,... Agent: The Hospital For Sick Children

20110091444 - Methods and compositions for treatment and prevention of major depressive disorder: The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abeta1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated levels of Abeta... Agent: New York University

20110091448 - Methods for regulation of stem cells: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian... Agent: Robarts Research Institute

20110091445 - Modulation of intestinal flora of hiv patients: The present invention is in the field of nutrition for HIV-infected subjects and concerns methods and composition comprising dietary fiber for the normalization of the intestinal flora of HIV-infected subjects.... Agent: N.v. Nutricia

20110091446 - Single domain antibodies capable of modulating bace activity: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications... Agent: Vrije Universiteit Brussel

20110091449 - Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies: This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.... Agent: The Trustees Of The University Of Pennsylvania

20110091450 - Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to... Agent: University Of Leicester

20110091452 - 4,5-dihydromacbecin derivatives and their use in the treatment of cancer or b-cell malignancies: The present invention relates to 4,5-dihydromacbecin analogues to the formula (IA) or (IB), or a pharmaceutically acceptable salt there of: wherein: R1 represents H or CONH2 that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases... Agent:

20110091458 - Anti-il 13 human antibodies: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.... Agent: Novartis Ag

20110091455 - Antibodies to myostatin: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or... Agent: Agouron Pharmaceuticals, Inc.

20110091457 - Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy: The invention relates to methods for predicting a clinical response to B-lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B-lymphocyte inhibiting or depleting... Agent:

20110091454 - Methods and systems for annotating biomolecular sequences: Polypeptide sequences and polynucleotide sequences are provided. Also provided are annotative information concerning such sequences and uses for these sequences.... Agent:

20110091451 - Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis: M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.... Agent:

20110091453 - Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory diseases: The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one... Agent: Medimmune, LLC

20110091456 - Treatment of neurological conditions: The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF or G-CSFR, a soluble G-CSFR or a G-CSF-binding... Agent: Csl Limited

20110091461 - Binding domain-immunoglobulin fusion proteins: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC... Agent: Trubion Pharmaceuticals, Inc.

20110091459 - Imidazole modulators of muscarinic acetylcholine receptor m3: The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110091460 - Receptor-targeting reagents: The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and... Agent: Regents Of The University Of Minnesota

20110091462 - Novel antigen binding dimer-complexes, methods of making and uses thereof: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or... Agent: Ablynx N.v.

20110091463 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Laboratories

20110091470 - Anti-flt3 antibodies: The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including... Agent: Imclone LLC

20110091469 - Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.... Agent: Immunex Corporation

20110091467 - Compositions and methods for modulating dopamine neurotransmission: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.... Agent: Center Of Addiction And Mental Health

20110091468 - Connective tissue growth factor antibodies: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those... Agent: Fibrogen, Inc.

20110091466 - Ige antibodies for the treatment of cancer: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is... Agent: The Regents Of The University Of California

20110091464 - Novel peptides and protein and uses thereof: The present invention relates to a novel gene encoding a protein termed Coiled Coil Domain Containing 95 (CCDC95) or a peptide fragments thereof. The present invention also relates to the use of CCDC95 in Modulation of RGK small binding protein via altering concentration or sub-cellular localisation of RGK small binding... Agent: Agency For Science, Technology And Research

20110091465 - Polypeptides: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.... Agent: Absynth Biologics Limited

20110091471 - Treatment method for epithelial cancerous organism: e

20110091472 - Compositions for treating psoriasis: CD40 antagonists are used to prepare compositions, including pharmaceutical compositions, for treating autoimmune and neoplastic diseases in a mammal. The CD40 antagonist compositions are useful for reversing or substantially diminishing such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and psoriasis.... Agent: Novartis Vaccines And Diagnostic, Inc.

20110091473 - Novel antibody therapies: Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has... Agent: Genmab A/s

20110091475 - Anti-human interleukin-20 antibodies: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods... Agent: Novo Nordisk A/s

20110091474 - Compositions and methods for diagnosing and treating diabetic micro vascular complications: Disclosed herein are compositions and methods for the identification of a subject at risk for developing microvascular complications associated with diabetes such as diabetic nephropathy and diabetic retinopathy. Also disclosed is a therapeutic target for the prevention and treatment of microvascular complications associated with diabetes.... Agent:

20110091476 - Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically... Agent: Medarex, Inc.

20110091478 - Methods of using antibodies against human il-22: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.... Agent: Wyeth LLC

20110091477 - Modulators of hepatocyte growth factor activator: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.... Agent: Genentech, Inc.

20110091479 - Novel anti-igf-ir antibodies and uses thereof: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid... Agent:

20110091480 - Antigen-binding proteins targeting s. aureus orf0657n: The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an S. aureus protein. ORF0657n target regions are provided by the mAb 1G3.BD4, mAb 2H2.BE11, mAb 13C7.BC1, and mAb 13G11.BF3 binding sites. In a lethal model challenge, mAb 2H2.BE11 and mAb... Agent:

20110091481 - Biomarkers for predicting response to immunosuppressive therapy: The subject invention concerns methods and materials for assessing a patient's likelihood of responsiveness to an immunosuppressive therapy. The subject invention is contemplated for use with patients having an autoimmune disorder. In an exemplified embodiment, the methods of the invention are used for assessing and/or treating a patient with MDS.... Agent: United States Department Of Veterans Affairs

20110091483 - Canine anti-cd20 antibodies: The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.... Agent: Idexx Laboratories, Inc.

20110091484 - Compositions and methods for preventing or treating a viral infection: The present invention is a composition for enhancing the immunogenicity of viral vaccine. The composition encompasses a viral vaccine in combination with at least one toll-like receptor and, in particular embodiments, an anti-CD40 antibody. The compositions of the instant invention find application in the prevention or treatment of a viral... Agent: Trustees Of Dartmouth College

20110091482 - Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis: The present invention is based on the finding that the level of KIR expression in a cancer cell is significant with regard to tumor invasion and metastasis. Therefore, the present invention concerns methods and compositions for evaluating cancer in a patient based on KIR protein or mRNA expression. The invention... Agent: The Regents Of The University Of Colorado, A Body Corporate

20110091486 - Inhibition of post-radiation tumor growth: Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.... Agent:

20110091487 - Melanoma biomarker and methods of uses: The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods for... Agent: Trustees Of Boston University

20110091485 - Modulation of cell junctions: The present invention provides methods of modulating cell junctions via the Gp140 membrane protein. Gp140 agonists and antagonists are provided, including activating and non-activating antibodies of Gp140, as well as compositions including the same. Methods of treatment including administration of a Gp140 agonist or antagonist are also provided. Finally, implants... Agent:

20110091488 - Water-swellable polymers: A pharmaceutical controlled release composition in solid dosage form is provided which comprises (I) a water-swellable linear polymer obtainable by reacting together: (a) a dried polyethylene oxide; (b) a dried C5 to C20 diol; and (c) a Bifunctional diisocyanate; and (II) a releasable pharmaceutically active agent.... Agent: Controlled Therapeutics (scotland) Limited

20110091492 - Escherichia coli immunogens with improved solubility: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.... Agent: Novartis Ag

20110091491 - Hiv-1 gp41 neutralization domain and use thereof: The invention relates to a region of the HIV-I gp41 protein that contains, at least in part, an epitope that allows potent neutralization of resistant virus particles. This site is present in the C-terminal heptad repeat region of gp41 (HR2), and adjacent to, but distinct from the MPER. Vaccines containing... Agent:

20110091490 - Novel vaccine for dog: This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the... Agent: Nippon Zenyaku Kogyo Co., Ltd.

20110091494 - Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant of the protective peptide; a composition comprising at least two protective peptides or functionally active variants thereof; a composition comprising at least two proteins selected from the group consisting of i) a... Agent: Intercell Ag

20110091489 - Survivin peptide vaccine: The present invention relates to a therapeutic vaccine comprising one or more survivin polypeptide fragments. The vaccine can be used for prophylactic, ameliorating and/or curative treatment of e.g. cancer diseases. The invention further relates to methods of combination treatment.... Agent: Survac Aps

20110091493 - Vaccine compositions and uses thereof: The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired... Agent: Northwestern University

20110091495 - Hcv e2 construct compositions and methods: A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal sequence, the ectodomain of HCV E2 sequence truncated at aa 664, a thrombin cleavage site and a human Fc domain. The... Agent: Rutgers, The State University Of New Jersey

20110091496 - Methods and compositions for the delivery of vaccines to disrupted epithelium: The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection.... Agent:

20110091497 - Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay: Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-MHC complexes are in many cases inadequate for a number of reasons. Disclosed herein is a reductionistic system incorporating known participants of MHC class II antigen processing in solution to... Agent: The Johns Hopkins University

20110091498 - Methods of stimulating an immune response against prostate specific antigen: The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for... Agent: The Usa As Represented By The Secretary, Dept. Of Health And Human Services

20110091499 - Treatment of pigs with pcv2 antigent: The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the... Agent: Boehringer Ingelheim Vetmedica, Inc.

20110091500 - Inactivated live-attenuated bluetongue virus vaccine: The invention describes the preparation of an inactivated bluetongue virus (BTV) composition, and in particular a vaccine, using an attenuated live BTV vaccine strain as masterseed. The vaccine can be administered to an animal to prevent bluetongue disease by eliciting an immune response against the bluetongue virus serotype(s) included in... Agent: Onderstepoort Biological Products Ltd.

20110091501 - Recombinant rhinovirus vectors: The invention provides rhinovirus vectors, which can be used in the delivery of immunogens, such as influenza virus immunogens, and corresponding compositions and methods.... Agent: Sanofi Pasteur Biologics Co.

20110091502 - Human parvovirus: humink parvovirus: Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Humink parvovirus, and variants thereof. Also provided are methods of detecting the Humink parvovirus and diagnosing Humink parvovirus infection, methods of treating or preventing Humink parvovirus infection, and methods for identifying anti-Humink parvovirus compounds.... Agent: Blood Systems, Inc.

20110091503 - Therapeutic composition with a botulinum neurotoxin: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good... Agent: Merz Pharma Gmbh & Co. Kgaa

20110091504 - Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.... Agent:

20110091505 - Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.... Agent:

20110091506 - Vaccine compositions: The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a Streptococcus pneumoniae capsular polysaccharide and a... Agent: Newcastle Innovation Limited

20110091507 - Schistosomiasis vaccine compositions and methods of use: No effective vaccine exists for the devastating parasitic disease of Schistosomiasis. The present invention focuses on Sm-p80, a functionally important antigen of Schistosoma mansoni that plays a pivotal role in the schistosome immune evasion process. When used in a novel vaccine formulation, Sm-p80 demonstrates consistent immunogenicity, protective potential, and antifecundity... Agent: Texas Tech University System

20110091509 - Benzonatate compositions and methods of use: Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications.... Agent:

20110091510 - Nanorod materials and methods of making and using same: The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the nanorod is composed of Zinc oxide (ZnO). In a further embodiment, a nanorod of the invention further comprises SiO2 or TiO2. In a specific... Agent: University Of Florida Research Foundation, Inc.

20110091508 - Oligofluorinated cross-linked polymers and uses thereof: The invention features oligofluorinated cross-linked polymers and their use in the manufacture of articles and coating surfaces.... Agent: Interface Biologics ,inc.

20110091511 - Transdermal delivery of drugs based on crystal size: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to... Agent: Noven Pharmaceuticals, Inc.

20110091512 - Highly porous, large polymeric particles and methods of preparation and use: The present invention relates to porous cross-linked polymeric particles having cavities joined by interconnecting pores wherein all or nearly all of the cavities at the interior of each particle communicate with the surface of the particle. The present invention also relates to a process for producing a porous, cross-linked large... Agent: Sunstorm Research Corporation

20110091513 - Water-dispersible and multicomponent fibers from sulfopolyesters: Disclosed are multicomponent fibers derived from a blend of a sulfopolyester with a water non-dispersible polymer wherein the as-spun denier is less than about 6 and wherein the water dispersible sulfopolyester exhibits a melt viscosity of less than 12,000 poise measured at 240° C. at a strain rate of 1... Agent: Eastman Chemical Company

20110091515 - Drug-eluting medical devices: Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures.... Agent: Ramot At Tel-aviv University Ltd.

20110091514 - Quaternary oxides and catalysts containing quaternary oxides: A quaternary oxide includes a dopant metal, a dopant nonmetal, titanium, and oxygen. The atomic ratio of titanium, oxygen and dopant nonmetal may be 1:0.5-1.99:0.01-1.5. Quaternary oxides may be used in catalytic compositions, in coatings for disinfecting surfaces and in coatings for self-cleaning surfaces. A method of making a quaternary... Agent:

20110091516 - Muscle-based grafts/implants: The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for... Agent: Regeneration Technologies, Inc.

20110091517 - Biocompatible scaffolds with tissue fragments: A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair. The biocompatible tissue... Agent: Depuy Mitek, Inc.

20110091519 - Controlling resorption of bioresorbable medical implant material: The resorption of a medical implant can be controlled with the use of particles embedded in a resorbable bulk material forming the implant or portion thereof. The implant can be removed from a body of a mammal by natural biological mechanisms after use. The resorption of the implant can involve... Agent: Boston Scientific Scimed, Inc.

20110091518 - Implant devices having varying bioactive agent loading configurations: Described herein are implant devices comprising various configurations of bioactive agent loading which can be selected and used to tailor a particular bioactive agent release profile from the implant device.... Agent:

20110091520 - Sustained release intraocular implants and methods for treating ocular neuropathies: Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix,... Agent: Allergan, Inc.

20110091521 - Edible spoon for dissociating into consumable predetermined clumps in order to prevent dissociating into random granules that would make consumption more difficult: An edible spoon for dissociating into consumable predetermined clumps in order to prevent dissociating into random granules that would make consumption more difficult. The edible spoon includes a bowl and a handle. The bowl extends from the handle and contains weakened lines. The weakened lines in the bowl define the... Agent:

20110091522 - Edible chew pill jacket: An edible chew pill jacket receives a pill/tablet or capsule that is to be administered to a pet, animal or human. The edible chew pill jacket includes a flexible top wall, side walls and bottom wall configured to form a chamber appointed to receive a pill. A flexible longitudinal slit... Agent:

20110091528 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.... Agent: Morehouse School Of Medicine

20110091529 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.... Agent: Morehouse School Of Medicine

20110091524 - Biomarkers for sensitivity to anti-igf1r therapy: The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.... Agent:

20110091523 - Cochleate compositions directed against expression of proteins: Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.... Agent: Biodelivery Sciences International, Inc.

20110091532 - Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient: Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement... Agent: Livechem, Inc.

20110091527 - Compositions and methods for reducing scar formation in wound healing: The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof. The healing wound may be a skin damage, but it may also be a myocardium e.g. which is at risk of suffering... Agent: Mosamedix B.v.

20110091531 - Cooling composition: A liquid cooling composition, which is a mixture of at least one primary cooling compound, at least one different secondary cooling compound and at least one ingestible non-polar solvent for the primary cooling compound, the weight ratios of primary cooling compound:secondary cooling compound:solvent being 1:1.5-2.25:2-4.4.... Agent: Giv Audan Sa

20110091530 - Oligopeptide tyrosinase inhibitors and uses thereof: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK (SEQ ID NO: 1) and YRSRKYSSWY (SEQ ID NO:... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110091526 - Parasite vaccine: Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein.... Agent: Imperial College Of London

20110091525 - Polyethyleneglycol-modified lipid compounds and uses thereof: The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.... Agent: Protiva Biotherapeutics, Inc.

20110091533 - Amphiphilic polymer capsules and related methods of interfacial assembly: Polymer capsules from amphiphilic graft copolymers comprising reactive, hydrophobic polyolefin backbones, and hydrophilic poly(ethylene glycol) (PEG) grafts are produced by self-assembly of the polymers at the oil-water interface, and crosslinking the assembly with bis-cyclooctene PEG derivatives in conjunction with ring-open metathesis polymerization catalysts. The use of the graft copolymer architecture... Agent:

20110091536 - Compositions comprising euphorbia prostrata and process of preparation thereof: Oral pharmaceutical compositions comprising dry extract of Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of Euphorbia prostrata is not more than about 500 microns with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful... Agent: Panacea Biotec Ltd.

20110091534 - Compositions comprising polymeric micelles for drug delivery: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.... Agent: Intezyne Technologies, Inc.

20110091535 - Solid pharmaceutical formulation: The present invention relates to a sustained-release solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch in an amount of 10 to 90% by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredients.... Agent:

20110091537 - Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile: e

20110091538 - Polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof: The present invention provides a Monodisperse Polymer Particles (MPP) adapted to release alkoxy groups by means of a hydrolyser, such that Monodisperse Bioactive Polymer Particles (MBPP) are obtained in vivo. The MBPP are characterized by (a) at least one naturally occurring or synthetic long molecular chain consisting of biologically stable... Agent: Z.h.t. Engineering Equipment And Technologies Ltd.

20110091539 - Micronized tanaproget and compositions containing same: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and... Agent: Wyeth LLC

20110091540 - Polymeric compositions and their method of use in combination with active agents: A combination of active agents is disclosed which are particularly useful for treating fluid overload conditions. Methods for using the combination of active agent are also disclosed. The combination can include a highly absorbent polyelectrolyte polymer along with an agent that increases the amount of fluid in the intestine.... Agent:

20110091541 - Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications: The present invention is characterized by the combination of two different technologies: one is the molecular encapsulation of AT11 receptor antagonists in cyclodextrins and the other is the microencapsulation in biodegradable polymers. It also comprises the increase of the effectiveness of the AT11 receptor antagonists as well as an increase... Agent: Universidade Federal De Minas Gerais

20110091542 - Baclofen and r-baclofen gastroretentive drug delivery systems: A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in the stomach and gastrointestinal tract of a patient, folded into a capsule... Agent: Intec Pharma Ltd.

20110091543 - Oral delivery of modified transferrin fusion proteins: Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such... Agent: Biorexis Pharmaceutical Corporation

20110091544 - Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting: Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the same are provided.... Agent: Acelrx Pharmaceuticals, Inc.

20110091545 - Direct injection moldable and rapidly disintegrating tablet matrix: The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.... Agent:

20110091546 - Composition for rapid disintegrating tablet in oral cavity: e

20110091547 - Pharmaceutical compositions comprising brivaracetam: The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.... Agent: Ucb Pharma, S.a.

20110091548 - Use of a matrix for orally administering sustained release magnesium, and composition containing said matrix: A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts... Agent:

20110091553 - Method for producing microcapsules using solid fat: An object of the present invention is to provide a method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production. The present invention... Agent: Kaneka Corporation

20110091550 - Methods for promoting the revascularization and reenervation of cns lesions: The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel.... Agent: Clemson University Research Foundation

20110091549 - Modulating drug release rate by controlling the kinetics of the ph transition in hydrogels: Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and... Agent: Confluent Surgical, Inc.

20110091552 - Use of bcl inhibitors for the treatment of scarring caused by cutaneous wounds, burns and abrasions: The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the... Agent:

20110091551 - Wound covering comprising octenidine dihydrochloride for use in the antisepsis of catheter insertion points: A wound covering includes a) a transparent film and b) applied to the film, a transparent hydrogel which includes octenidine dihydrochloride. The wound covering is suitable in particular for use in the antisepsis of catheter insertion points. The active ingredient octenidine dihydrochloride is released from the hydrogel quickly, but in... Agent: Lair Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Claude

20110091554 - Injectable composite material suitable for use as a bone substitute: The invention relates to a new injectable composite material suitable for use as a bone substitute. The composite material according to the invention comprises a reactive ceramic phase based on tricalcium phosphate and an organic phase comprising a polyvinyl alcohol hydrogel. By varying the concentration of the two phases it... Agent: Consiglio Nazionale Delle Ricerche

20110091555 - Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders.: e

20110091556 - Antimicrobial compositions and methods of use: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present... Agent:

20110091557 - Composite material: The invention relates to a composite material, a precursor for forming the composite material and a method of forming the composite material from the precursor. The invention also relates to the use of said composite material and in particular to its use as an antibacterial or antimicrobial agent.... Agent: Smith & Nephew PLC

20110091559 - Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof: The invention is directed to compositions comprising an oil adjuvant, a macrocyclic lactone effective for the prevention or control of parasitic infection in a warm-blooded animal and an immunizing amount of at least one immunogenic polypeptide and methods of use thereof.... Agent: Wyeth LLC

20110091560 - Compositions of nanoparticles and methods of making the same: Disclosed herein are compositions of nanoparticles. In some embodiments, the nanoparticles are Janus particles, where each particle includes a first component and second component that are exposed to the surface of the particle. Also, disclosed are methods and systems for making a composition of nanoparticles. Finally, a method of treating... Agent: The Burnham Institute For Medical Research

20110091561 - Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer: The present invention provides stable perfluorcarbon nanoemulsions with endocytosis enhancing surfaces that are suitable for gene-transfer, its production and use.... Agent: Soluventis Ug

20110091558 - Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability: The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone,... Agent: Wockhardt Research Centre

20110091562 - Nanogels for cellular delivery of therapeutics: The various embodiments of the present disclosure relate generally to nanogels for the cellular delivery of therapeutics and methods of using the same. More particularly, the various embodiments of the present invention are directed to systems and methods for the targeted treatment of neoplastic using nanogel-based technologies. In an embodiment... Agent: Georgia Tech Research Corporation

20110091563 - Orally-disintergrating solid preparation: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting... Agent: Takeda Pharmaceutical Company Limited

20110091564 - Injectable hollow tissue filler: The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of... Agent:

20110091565 - Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to... Agent:

20110091566 - Controlled release pharmaceutical compositions: The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises: (a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 25% by weight of a water-insoluble polymer applied as an aqueous latex... Agent:

20110091569 - Echinoderm-derived extracts, methods of preparation and uses thereof: An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of... Agent: Rival, Sec

20110091568 - Media conditioned by stem cells and uses therefor: Compositions for application to the skin of individuals in need thereof are provided that include media conditioned by the growth of human stem cells, particularly human neural stem cells. In some embodiments, the stem cells are grown without the use of feeder layers.... Agent:

20110091567 - Tissue organizing structure and therapeutic methods: A novel cellular component, tissue organizing structure, and methods for use in detection, diagnosis and treatment of disease is described herein. Particularly, clinical applications include tissue generation from individual cellular components, gene transfer therapeutics and its use as a novel target for cancer prevention and therapeutics. More particularly, methods for... Agent:

20110091570 - Compositions and devices for antisepsis and anticoagulation: Disclosed herein are compositions, methods, uses, and devices having antiseptic and anticoagulation properties in a mammal. The compositions, methods, uses, and devices are based on a therapeutically effective amount of one or more N-halogenated or N,N-dihalogenated amines, analogues or derivatives thereof, or pharmaceutically acceptable salts and esters. The preferred compound... Agent:

20110091572 - Acne treatment compositions comprising nanosilver and uses: This invention is directed to improved compositions for treatment of acne and related methods. In some embodiments, the present invention is directed to compositions comprising a topical vehicle, nanosilver, acne medicine and soothing agents, effective for treating acne without irritation.... Agent:

20110091571 - Method of controlling the propagation of mrsa, staph and other infections that colonize in the nose: A method or protocol for reducing the spread of bacterial infections such as MRSA among a population includes identifying a group of individuals at risk of carrying or becoming carriers of a bacterial infection that colonizes in the nose, determining whether any individuals can be excluded from treatment due to... Agent:

20110091573 - Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.... Agent: Memorial Sloan-kettering Cancer Center

20110091574 - Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor: Methods of treating adenocarcinoma cells such as NSCLC cells are disclosed that depend upon the level of functionally active LKB1 expressed in the cancer cells being treated. In one embodiment, the cancer cells express functionally active LKB1 and the method comprises contacting those cells with a LKB1-stimulating amount of a... Agent: Catholic Healthcare West

20110091575 - Strategies for reducing leaching of water-soluble metal biocides from treated wood products: Strategies that dramatically reduce leaching of water-soluble metal-containing biocides from treated biodegradable products. Aqueous, preservative compositions of the present invention incorporate one or more water-soluble metal species having biocidal activity and one or more agents that increase the leaching resistance of these metal species when impregnated into biodegradable products. Using... Agent:

20110091576 - Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growrh factors of stem cells: r

20110091577 - Drug release coatings on calcuim phosphate and uses thereof: The invention provides implantable drug releasing materials comprising a calcium phosphate composition, a biodegradable polymer adsorbed onto the calcium phosphate composition, wherein the polymer comprises acidic amino acid residues, and a drug adsorbed onto or reacted with the polymer. The invention is further directed to dental and bone implants and... Agent:

20110091578 - Method of stimulating tissue healing: A method of stimulating tissue healing in humans or animals includes administering to a human or animal suffering from lesions and infections linked to chronic and/or acute periodontitis a pharmaceutically effective amount of a pharmaceutical composition including (i) at least one sodium halopohalite, and (ii) at least one N-halogenated taurine,... Agent:

20110091579 - Vitamin d2 enriched mushrooms and fungi for treatment of oxidative stress, alzheimer's disease and associated disease states: An filamentous fungi is disclosed with a naturally vitamin D enriched nutritional profile. These enriched mushrooms were shown to have a synergistic effect on longevity of subjects with both a normal and nutritionally deficient diets, improved tolerance to oxidative stress, and increased longevity in a Alzheimer's disease model. Surprisingly, vitamin... Agent: Total Nutraceutical Solutions, Inc.

20110091583 - Antiallergic marine biopolymers: The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention... Agent: Marinomed Biotechnologie Gmbh

20110091580 - Extract of rosmarinus officinalis l. leaves for pharmaceutical applications: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50%... Agent: Naturex, S.a.

20110091582 - Method for obtaining concentrated polyphenol extracts from a stirring process: The present invention proposes methods for obtaining concentrated polyphenol extracts resulting from the stirring process, through a step in which a partially purified beer is placed into contact with a resin that adsorbs the polyphenols, followed by a step in which the polyphenols adsorbed onto said resin are recovered. The... Agent:

20110091581 - New pharmaceutical function of dichroa febrifuga alkone derivative (dfad): A safe pharmaceutical composition for antioxidation, controlling oncoges, inhibiting tyrodine kinase activity and increasing immune function contains dichroa febrifuga alkone derivative (DFAD).... Agent:

20110091584 - Lymphatic vessel stabilizer: Provided is a lymphatic vessel stabilizer composed of Tie2 activator. The Tie2 activator is preferably at least one type selected from the group consisting of angiopoietin 1 (Ang-1), extract of Cinnamomum species plants, extract of Siberian Ginseng and syringaresinol.... Agent: Shiseido Company, Ltd.

20110091585 - Herbal compositions and methods for enhancing vital energy and athletic performance: Compositions, kits and methods are provided for enhancing vital energy and athletic performance, improving or restoring blood circulation, promoting mental acuity, reducing fatigue, and improving aerobic performance. In one embodiment, the composition comprises the herbal extracts of Rhodiola crenulata (root) and Ginkgo biloba (leaf). The composition can be used as... Agent: Integrated Chinese Medicine Holdings Ltd.

20110091586 - Compositions containing amines and use thereof: m

20110091587 - Phase ii detoxification and antioxidant activity: Provided are methods and compositions that enhance Nrf2 (SKN-1) activation of phase II detoxification or antioxidant enzyme transcription, comprising plant extracts (e.g., willow extracts) or active fractions thereof, as well as methods for identifying additional compounds that increase the Nrf2-regulation of those enzymes.... Agent: Sunstar Inc.

20110091588 - Orchid vanda coerulea as a cosmetic active agent: An extract of the orchid Vanda coerulea is used as cosmetic active agent for regulating the cell cycle in the skin to combat or delay the appearance of visible signs of skin aging or slow down the effects thereof. The extract is used in a cosmetic composition or in an... Agent: Lvmh Recherche

20110085968 - Articles comprising nano-materials for geometry-guided stem cell differentiation and enhanced bone growth: The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and/or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their... Agent: The Regents Of The University Of California

20110085969 - Chelator-targeting ligand conjugates for cardiovascular imaging: Disclosed are methods of imaging a site in a heart of a subject to detect cardiovascular disease that involve stressing a subject, administering to the stressed subject an effective amount of a radionuclide-labeled chelator-glucose analog conjugate, and imaging the heart of the subject by detecting a signal generated by the... Agent:

20110085970 - Anti-b7h4 monoclonal antibody-drug conjugate and methods of use: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules... Agent:

20110085973 - Methods and agents for the diagnosis and treatment of hepatocellular carcinoma: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to... Agent: China Synthetic Rubber Corporation

20110085971 - Nanotubes for cancer therapy and diagnostics: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.... Agent:

20110085972 - Nanotubes for cancer therapy and diagnostics: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.... Agent:

20110085974 - Small molecule ligand-drug conjugates for targeted cancer therapy: The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.... Agent: Emory University

20110085975 - Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy... Agent: Natural Pharmacia International, Inc.

20110085979 - Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions: e

20110085976 - Methods for detecting cardiac damage: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart... Agent: Acorda Therapeutics, Inc.

20110085978 - Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors: This invention provides novel quinolinylamide derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, 5HT1A and 5-HT2A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.... Agent: Neurosearch A/s

20110085977 - Use of utp for the diagnosis of stenoses and other conditions of restricted blood flow: The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively... Agent:

20110085980 - Cell cycle regulation and differentiation: The present invention provides compositions and methods for regulating neural cell proliferation or differentiation. The present invention also provides methods for selecting for bioactive agents effective in regulating proliferation or differentiation.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110085982 - Dkat cell line, a model for human triple-negative breast cancer: The present invention provides a human triple-negative breast cancer cell line designated DKAT. The DKAT cell line has a marker profile of high expression of Snail-1 and Snail-2 (Slug); and a p53 mutation in exon 8 at codon 273 (CGT>CAT). The present invention further provides methods of using the DKAT... Agent: Duke University The Regents Of The University Of California

20110085984 - Drug product and process for making: The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from... Agent:

20110085981 - Glycan-based drugs, therapies and biomarkers: The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and... Agent:

20110085983 - Liquid chromatography-mass spectrometry methods for multiplexed detection and quantitation of free amino acids: The present invention provides liquid chromatography-mass spectrometry methods and kits for the specific, sensitive and rapid detection as well as quantitation of free amino acids in samples following High Pressure Liquid Chromatography (HPLC) separation.... Agent: The Boards Of Trustees Of The Leland Stanford Junior University

20110085985 - Novel substituted azabenzoxazoles: The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron... Agent:

20110085987 - Folic acid-mediated magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications: The preparation method of the magnetic nanoparticle (MNP) includes steps of: (a) reacting folic acid (FA) with Pluronic F127 (PF127) to form FA-PF127; (b) reacting poly(acrylic acid) (PAA) with FeCl3 to form PAA-bound iron oxide (PAAIO); and (c) reacting FA-PF127 with PAAIO via N-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) mediation to form FA-PF127-PAAIO.... Agent: Kaohsiung Medical University

20110085986 - Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides: The current invention provides Progastrin peptides that specifically bind Annexin A2 overexpressed by epithelial cancers. The invention includes isolated homing Progastrin peptides conjugated to an imaging agent and methods of using the same for the diagnosis of epithelial cancers. Also encompassed are Progastrin peptides conjugated to cytotoxic agents such as... Agent:

20110085988 - Swollen silicone composition, process of producing same and products thereof: There is provided herein, in one specific embodiment, silicone composition(s) comprising unique combination(s) of silicone polymer and alkyltrisiloxane(s) which can produce silicone composition(s) with lower solids content than silicone compositions that use other than alkyltrisiloxane(s); while still maintaining a desirable viscosity.... Agent: Momentive Performance Materials, Inc.

20110085989 - Novel antimicrobial peptides: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.... Agent: C3 Jian, Inc.

20110085991 - Compositions for enhancing effects of other oral care compositions: An enhancing composition comprising a solvent and a base compound creates an alkaline environment for activating peroxide whiteners and accelerating the formation of free radicals from the peroxide to effect the oxidation of organic molecules causing staining of the dentition. In one embodiment, potassium hydroxide is dissolved in water to... Agent:

20110085990 - Oral care methods and systems: This, intention relates to methods of assessing the biofiora of the mouth and of providing appropriate treatment utilizing a basic amino acid in accordance with the assessment.... Agent: Colgate-palmolive Company

20110085992 - Composition for preventing infection of new influenza a (h1n1) virus comprising ginkgo extract, air filter comprising the same, and air cleaning device comprising the filter: Disclosed are a composition for the prophylaxis of new influenza A (H1N1) virus infection comprising a ginkgo extract, an air filter coated with the same, and an air cleaner comprising the air filter. Having high inhibitory activity against new influenza A (H1N1) virus, the composition comprising a ginkgo extract can... Agent: Woongjin Coway Co., Ltd.

20110085996 - External preparation composition for skin comprising ginseng flower or ginseng seed extracts: Provided are a use of a ginseng flower extract and a use of a ginseng seed extract. The ginseng seed extract includes ginseng seed oil or a ginseng seed residue extract. The uses include skin protection, anti-aging, anti-wrinkle, improvement of skin elasticity, skin whitening, skin moisturizing, prevention and improvement of... Agent:

20110085995 - Opacifying polymers: A self-stabilizing dispersion composition having a copolymer having at least one polymerizable acid-containing moiety, wherein the at least one acid-containing moiety is at least partially neutralized before or during polymerization, and at least one hydrophobic moiety. A process for producing such compositions is also provided, as well as a process... Agent: Akzo Nobel N.v.

20110085994 - Sunscreen compositions: The present invention provides a taste-masked sunscreen composition comprising at least one sunscreen and a spider ester wherein the sunscreen and the spider ester are in intimate association. A method of making the taste-masked sunscreen composition is provided.... Agent: Wyeth LLC

20110085993 - Use of creatine or creatine compounds for skin preservation: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary... Agent: Avicena Group, Inc.

20110085997 - Compositions based on polyester in an oily phase and uses thereof: The present invention relates to a cosmetic make-up or care composition comprising an oily phase comprising at least one liquid polyester obtained by condensation of unsaturated fatty acid dimer and/or trimer and diol, said composition being free from lipophilic gelling agent or comprising at the most 10 wt. % thereof,... Agent: L'oreal

20110085999 - Use of at least one (dihydro)jasmonic acid derivative for treating dry skin: A cosmetic process for treating dry skin and/or a dry scalp of non-inflammatory origin, for example, in a menopausal woman, comprising topically applying to the skin and/or the scalp a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative; novel (dihydro)jasmonic acid derivatives and to the... Agent: L'oreal S.a.

20110085998 - Mascara composition: Mascara compositions containing a keratin conditioning agent, alone or in combination with an emollient/moisturizing agent, provide increased resistance of eyelash hair fibers to breaking. Low viscosity mascara composition of the invention containing low concentrations of surfactant and wax are easily removable from the eyelashes. Mascara compositions of the invention reduce... Agent: Avon Products, Inc.

20110086000 - Novel skin peel composition in masque form: The present invention is directed to a method of reducing the appearance of skin changes associated with intrinsic and/or extrinsic aging, involving the steps of: (a) providing a first composition containing: (i) from about 20 to about 50% by weight of at least one hydroxy acid; (ii) optionally, from about... Agent: L'or&#xc8 Al S.a.

20110086001 - Compliant biocompatible polymer compositions for medical uses: Phase-separated elastomeric biocompatible polymer compositions are disclosed that are bioresorbable and/or biodegradable, and are useful in a variety of medical applications in which a low modulus polymer is desired, such as in the fabrication of medical devices.... Agent: Rutgers University

20110086004 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc.

20110086005 - Modulating interstitial pressure and oncolytic viral delivery and distribution: Provided herein are methods of treating a proliferative disorder in a subject comprising decreasing interstitial pressure and/or increasing vascular permeability in the subject and administering to the subject an oncolytic virus. Such methods improve oncolytic viral delivery and distribution.... Agent: Oncolytics Biotech Inc.

20110086002 - Restoration of hearing loss: The present invention relates to compositions and methods for restoring hearing loss. In particular aspects, the invention relates to the administration of compositions that encode an inflammatory response control element. The compositions are prepared and administered in such a manner that the inflammatory response control element coding sequence is expressed... Agent:

20110086003 - Stabilization of hydrophobic protein therapeutic agents: The present invention relates to a stabilized solution comprising a hydrophobic protein, a method for the production thereof, and the stabilizing solution as a pharmaceutical, and the use thereof.... Agent: Stiftung Tierarztliche Hochschule Hannover

20110086006 - Hcv ns3-ns4 protease resistance mutants: The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.... Agent: Vertex Pharmaceuticals Incorporated

20110086011 - Prevention or treatment of immune-relevant disease by modification of microfloral populations: The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.... Agent:

20110086009 - Cell line for the production of prostacyclin and uses thereof: Provided herein are methods for producing a biomolecule by converting or engineering a plurality of cells, e.g., mammalian cells, having an endogenous precursor of a biomolecule to cells transfected to contain a nucleic acid that stably overexpresses a hybrid enzyme effective to metabolized the precursor to the biomolecule in the... Agent:

20110086008 - Composition and method for the repair and regeneration of cartilage and other tissues: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere... Agent:

20110086007 - Epidermal stimulation to enhance hair follicle formation: The present invention features a method for improving the efficiency of hair formation by follicular cell implantation. The method includes the use of epidermal stimulation (ES) to stimulate keratinocytes in a subject's skin in order to make them more receptive to hair inductive signals originating from implanted follicular cells (e.g.... Agent: Aderans Research Institute, Inc.

20110086010 - Methods, systems, and apparati for cellular therapeutic agent preparation and delivery: Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's... Agent:

20110086012 - Rejuvenation method: A rejuvenation method includes a) removing blood or tissue from a human body or animal body, b) nurturing and purifying the blood or tissue, and c) implanting the blood or tissue that has been nurtured and purified into a user to increase the amount of stem cells in the user... Agent:

20110086013 - Acylglycerol acetyltransferase-like protein mgat-x1 and uses thereof: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides... Agent: Bayer Schering Pharma Ag

20110086014 - Method for enzymatic cross-linking of a protein: A method for cross-linking albumin for use as a sealant or glue for a biological system, for example to induce hemostasis and/or prevent leakage of any other fluid from a biological tube or tissue, such as lymph for example. The cross-linked albumin may optionally and preferably be applied as part... Agent:

20110086015 - Zinc finger nuclease for the cftr gene and methods of use thereof: The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.... Agent:

20110086016 - Enzymatic pre-mixture against gram negative bacteria colonization in the animal intestinal tract: The invention provides pre-mixture for animal feeding comprising: (a) a polymer or a mixture of polymers, with a content in mannose comprised between 10% and 100%; (b) β-mannanase enzyme; and (c) an anti-binding agent; wherein the anti-binding agent has an absorptive capacity higher than 20%, and a bulk density which... Agent: Industrial T&#xc9 Cnica Pecuaria, S.a.

20110086017 - Medical food composition and methods for management of inflammatory processes in mammals: A medical food composition, containing at least source of milk protein derived from milk producing animals, exposed to immune stimulants during pregnancy and lactation period, source of Curcuminoids, source of proteolytic enzymes, and source of Piperin effective to manage inflammatory response and associated pain symptoms in mammals.... Agent:

20110086018 - Proteinases destroy cancer tumor's solid structure and kill cancer cells locally: A proteinase therapy has been invented to eliminate solid tumors by destroying tumors' solid structure and killing cancer cells by cleaving vital extracellular matrix proteins C-terminally, N-terminally or both with cell membrane intact and limited adverse effects. The micro-scale intratumoral proteinase K therapy is tumor specific but not cancer type... Agent: Biomedicure

20110086020 - Agent exhibiting immunoregulatory properties and the use thereof for treating autoimmune diseases: The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multivalent ligand G (Ig-G) or A (Ig-A) or... Agent:

20110086022 - Methods for diagnosing and treating neuroendocrine cancer: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.... Agent: Trustees Of Dartmouth College

20110086019 - Polypeptides, antibody variable domains and antagonistsmethods for: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for... Agent: Domantis Limited

20110086021 - Sclerostin and the inhibition of wnt signaling and bone formation: The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt... Agent: Enzo Therapeutics, Inc., C/o Enzo Biochem, Inc.

20110086023 - Combination antihistamine medication: The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a mucosal adjuvant, (3) an antihistamine drug and (4) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin,... Agent: Fairfield Clinical Trials LLC

20110086027 - Anti-cxcr4 antibodies: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.... Agent: Eli Lilly And Company

20110086026 - Antibodies against il-13 receptor alpha 1 and uses thereof: An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3,... Agent:

20110086025 - Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent:

20110086024 - Use of antagonists of the interaction between hiv gp120 and a4b7 integrin: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the... Agent: The Government Of The Usa

20110086030 - Inhibition of cancer metastasis: The present invention provides methods for inhibiting tumor cell metastasis. In particular, the invention provides methods for reducing tumor cell malignancy by administering to a subject an antibody that inhibits glycoprotein Ibα, such that tumor cell malignancy is reduced.... Agent: Board Of Trustees Of The University Of Arkansas

20110086031 - Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders: The present invention provides a method of treating diseases or disorders benefiting from inactivating or down-regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a... Agent:

20110086029 - Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.... Agent: The Regents Of The University Of California

20110086028 - Prevention of hiv infection: This invention relates to methods compositions and devices for inhibiting infection of a subject's host cell by HIV. Specifically, the invention relates to methods and compositions capable of inhibiting the binding and subsequent infection by HIV of a host cell through the inhibition of the interaction between gp-340 expressed on... Agent: The Trustees Of The University Of Pennsylvania

20110086032 - Anti-fgf19 antibodies and methods using same: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.... Agent: Genentech, Inc.

20110086035 - Immunotherapeutic methods and molecules: A peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTI DWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two of the amino acid residues are altered, wherein the portion or variant is capable of binding HLA-DRB1*04. The... Agent: Cell Medica Limited

20110086033 - Method of inhibiting osteoclast activity: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.... Agent: Immunex Corporation

20110086034 - Nucleotide and protein sequences of nogo genes and methods based thereon: The present invention relates to the gene, $i(Nogo), its encoded protein products, as well as derivatives and analogs thereof. Production of Nogo proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy.... Agent:

20110086036 - Composition comprising vlp and amyloid beta peptide: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the... Agent:

20110086037 - Method of treating inflammatory disorders: Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a... Agent:

20110086038 - Interleukin-13 antibody composition: The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis,... Agent: Medlmmune Limited

20110086039 - Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors: This invention relates generally to a therapeutic use of epidermal growth factor receptor inhibitors to reduce fibrosis, e.g., liver fibrosis, or pre-cirrhosis in a subject.... Agent: General Hospital Corporation, The

20110086040 - Method of treating hemolytic disease: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.... Agent: Alexion Pharmaceuticals, Inc.

20110086041 - Fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies: Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation... Agent: Children's Medical Center Corporation

20110086042 - Centrosomal proteins, nucleic acids and method of use thereof: The present invention provides novel isolated centrobin polynucleotides and polypeptides encoded by the centrobin polynucleotides. The invention additionally provides methods of inhibiting cell growth by contacting a cell with a centrobin inhibitor.... Agent:

20110086044 - Compositions and methods to inhibit hpv infection: This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV... Agent: University Of Southern California

20110086045 - Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract: A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a... Agent: Wisconsin Alumni Research Foundation

20110086043 - Stat5a and its functional tumor suppressor analogs for treatment of malignancies expressing npm/alk and other oncogenic kinases: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing... Agent:

20110086048 - Detection of human immunodeficiency virus co-receptor tropism in aviremic subjects: Methods for detecting human immunodeficiency virus (HIV) co-receptor tropism or replication-competent virus in aviremic subjects, and methods of selecting optimal therapies for aviremic subjects.... Agent: University Of Massachusetts

20110086047 - Fc receptor homolog antibodies and uses thereof: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and... Agent: The Uab Research Foundation

20110086049 - Receptor modulators: Method of identifying a modulator of CD28 comprising comparing a structural model of a candidate modulator with a structural model of CD28 to thereby determine whether the modulator will bind to CD28, wherein the structural model is derived from, or comprises, structural coordinates of a crystal of: (i) CD28, (ii)... Agent: Isis Innovation Limited

20110086046 - Treatment of ms with goat serum: A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal.... Agent:

20110086050 - Glycoprotein compositions: The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.... Agent:

20110086052 - Activation of innate and adaptive immune responses by a ginseng extract: The invention is directed to ginseng fractions and methods for activating innate and adaptive immune responses to prevent, treat or ameliorate a condition in a subject by administering to the subject an effective amount of a ginseng traction, a pharmaceutical composition comprising the fraction in combination with another medicament or... Agent:

20110086053 - Glycolipids and analogues thereof as antigens for nkt cells: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.... Agent: The Scripps Research Institute

20110086051 - System and method for monitoring and optimizing immune status in transplant recipients: This invention provides a system and method for an assay used in determining appropriate immunosuppressant levels relative to organ transplant in which PBMC is separated from whole blood by Ficoll®. An aliquot of PBMC is used for phenotyping of cells. CD4, CD8, memory and naïve subsets, B-cells regulatory T-cells and... Agent: Dartmouth-hitchcock Clinic

20110086054 - Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose: Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal α-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines.... Agent:

20110086055 - Her2 peptides: Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.... Agent: The Ohio State University Research Foundation

20110086056 - Methods for the early diagnosis of ovarian cancer: The present invention discloses the protease hepsin is specifically over-expressed in ovarian and other malignancies. A number of hepsin peptides can induce immune responses to hepsin, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. There is also provided a... Agent:

20110086057 - Ox40r binding agents: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with... Agent: Merck Serono Sa

20110086058 - Immunopotentiator-linked oligomeric influenza immunogenic compositions: Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence... Agent:

20110086059 - Non-hemolytic clya for excretion of proteins: The disclosure below provides a protein export system utilizing non-hemolytic variants of HlyE family member proteins for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is... Agent: University Of Maryland, Baltimore

20110086060 - Novel compositions and their use: The present invention relates to a composition comprising panthenol, a collagen synthesis stimulating peptide and an anti-inflammatory extract. The compositions are particular useful for preventing and treating stretch marks.... Agent:

20110086061 - Cancer detection methods and reagents: The present invention comprises methods and compositions for detecting cancer in an individual comprising autoantibodies to cancer-associated antigens. Specifically, the present invention comprises methods and compositions for detecting autoantibodies to cancer-associated antigen in a bodily fluid as well as use of said autoantibodies as a means to detect the presence... Agent: Onclmmune Limited

20110086062 - Alphavirus replicon particles matched to protein antigens as immunological adjuvants: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and... Agent: Alphavax, Inc.

20110086063 - Vaccines for prevention and treatment of addiction: The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The... Agent: Cornell University

20110086064 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin: Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed.... Agent: Thomas Jefferson University

20110086065 - Lentival vector-based vaccine: Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed.... Agent:

20110086066 - Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.... Agent:

20110086067 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization... Agent: Central Iowa Health System

20110086074 - Combinations of niacin and an oxicam: Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations.... Agent: Dr. Reddy's Laboratories, Inc.

20110086068 - Compositions and methods for tissue engineering, tissue regeneration and wound healing: In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein... Agent: University Of South Carolina

20110086073 - Nanometer-sized prodrugs of nsaids: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.... Agent: Cedars-sinai Medical Center

20110086070 - Orally disintegrating compositions of rhein or diacerein: The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions.... Agent:

20110086071 - Pharmaceutical compositions comprising terbinafine: This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration.... Agent:

20110086069 - Pharmaceutical formulations of nitrite and uses thereof: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion... Agent: Theravasc, LLC

20110086072 - Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.... Agent:

20110086076 - Compact powder for skin care or for making up the skin: The subject of the present invention is a compact powder which is soft and creamy on application, and which contains a filler composed of a substrate in the form of platelets, arranged at the surface of which are particles which have an average size of between 5 nm and 10... Agent: Chanel Parfums Beaute

20110086075 - Personal care sunscreen compositions having reduced eye irritation: The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulite composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters... Agent:

20110086078 - Fibrous antimicrobial materials, structures, and barrier applications: Fibrous antimicrobial materials for use in structures and barrier applications, such as face masks and wound dressings, have been developed from antimicrobial polymeric materials. The fibrous antimicrobial materials also are particularly suitable for use in air and water filtration. The antimicrobial polymeric materials are prepared from solid solutions of antimicrobial... Agent: Hydropure, LLC

20110086077 - Silicone hydrogels for tissue adhesives and tissue dressing applications: A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone... Agent: The Polymer Technology Group, Inc.

20110086079 - Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations: The present invention relates to a method for producing hair microfollicles comprising the steps of: a) providing de novopapillae, b) providing other cell populations selected from the group of fibroblasts, keratinocytes and melanocytes, and co-culturing the de novopapillae with at least one other cell population in non-adherent culture vessels. The... Agent:

20110086081 - Coating system and method for drug elution management: The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional endothelium over a surface of the medical device.... Agent: Specialized Vascular Technologies, Inc.

20110086082 - Composition, system, and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility: An implantable drug delivery device loaded with a beneficial agent is provided, wherein the beneficial agent is in two different forms, a first form having a higher solubility and a second form having a lower solubility, and wherein the two different forms are present in a proportion which is selected... Agent: Innovational Holdings, LLC

20110086080 - Ex-vivo production of human demineralized bone matrix: The present disclosure provides ex vivo-derived human demineralized bone matrix. The bone matrix is produced using mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating... Agent: Osteosphere, LLC

20110086083 - Implant devices for modulating bioactive agent release profiles: Described herein are implant devices comprising at least one exposed biodegradable inner core surface, the inner core being surrounding partially by a membrane sheath which comprises a biocompatible polymer. A bioactive agent can be released from the inner core.... Agent:

20110086084 - Active agent containing polymer network delivery composition and articles using the same: Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a polymer network and a volatile component incorporated into the polymer network to stabilize the volatile for extended periods of time. The... Agent:

20110086085 - Carbohydrate entrapped active agent delivery composition and articles using the same: Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time.... Agent:

20110086086 - Transdermal system for varenicline: The invention provides transdermal compositions comprising varenicline or its pharmaceutically acceptable salt or prodrug form.... Agent: Pfizer Inc

20110086088 - Compositions and methods for treatment of mammalian skin: Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure. In other embodiments,... Agent:

20110086087 - Process and formulation for immunizing fish in aquaculture systems: Process, use, method and formulation of inclusion of Deoxyribonucleic acid (DNA) in food compositions for livestock animals, in particular in aquacultural systems.... Agent: Ewos S.a.

20110086091 - Stable crystal modifications of dopc: The invention relates to stable crystal modifications of (R,S)-, (R)- and (5S)-DOPC, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.... Agent: Merck Patent Gesellschaft Mit Beschr&#xc4 Nkter Haftung

20110086089 - Use of p27kip1 for the prevention and treatment of heart failure: p27KIP1 (p27) blocks cell proliferation through inhibition of FIG. 6 cyclin-dependent kinase 2 (dk2)1. Despite its robust expression in the heart2,3, little is known about both the function and regulation of p27 in this and other non-proliferative tissues, where the expression of its main target, cyclin E-Cdk2 is known to... Agent: University Health Network

20110086090 - Vectors containing the max gene: The present invention refers to the construction of cloning vectors containing the max gene. Especially, the present invention refers to the introduction of cloning vectors containing the max gene in cells using transport vectors. In addition, the presence of cloning vectors containing the max gene in cells allows the differential... Agent: Universidade Federal Do Rio De Janeiro

20110086093 - Method for increasing lactose tolerance in mammals exhibiting lactose intolerance: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day... Agent: Ritter Pharmaceuticals, Inc.

20110086092 - Pharmacuetical tablets containing a plurality of active ingredients: Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry-over and intermixing are minimized in the manufacture process.... Agent: Accu-break Technologies, Inc.

20110086094 - Capsule for the prevention of cardiovascular diseases: The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.... Agent: Fundacion Centro Nacional De Investigaciones Cardi Ovasculares Carlos Iii

20110086095 - Bioadhesive polymers: Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently... Agent: Spherics, Inc

20110086096 - Modified release 1- [ (3-hydroxy-adamant-1-ylamino)-acetyl] -pyrrolidine-2 (s) -carbonitrile formulation: l

20110086097 - Manufacture process for the preparation of an iron containing phosphate adsorbent: The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.... Agent:

20110086098 - Rapidly disintegrating gelatinous coated tablets: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage... Agent:

20110086099 - Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns... Agent: K.u. Leuven Research & Development

20110086101 - Dispersinb, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof: The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides... Agent:

20110086100 - Polyethylene glycol aerogels for targeted delivery of pharmaceutical drubs: A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2μ, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst... Agent:

20110086102 - Delayed release compositions: The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating.... Agent: Teva Pharmaceutical Industries Ltd.

20110086103 - Novel mandelate salt of fesoterodine: Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing... Agent: Actavis Group Ptc Ehf

20110086104 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a... Agent: Alkermes, Inc.

20110086106 - Method of producing a dry earthworm powder: Provided is a simple and easy method of producing an innoxious dry earthworm powder, while suppressing inactivation of the enzymes contained in earthworms. In the method, a homogenate obtained by grinding living earthworms is freeze-dried and the dried product is heat-treated at a temperature of 110° C. or higher but... Agent:

20110086105 - Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation: Described herein are methods for identifying novel nucleic acid regulatory elements and compounds that modulate the regulation of such elements. Also described herein are nucleic acid sequence identified as novel nucleic acid regulatory elements and host cells containing such nucleic acid regulatory elements in a vector.... Agent:

20110086107 - Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the... Agent: Air Liquide Sante (international)

20110086108 - Dissolving powders that can be mixed with water and used as an oral rinse: This invention involves the formulation of stable powders which, when dissolved in water form a non-pressurized carbonated solution supersaturated with calcium and phosphate ions, and also containing the presence of carbon dioxide and sodium bicarbonate. The resulting solution is used as an oral rinse for the prevention and treatment of... Agent:

20110086109 - Low ether compositions and delivery apparatus: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time... Agent: Schering-plough Healthcare Products, Inc.

20110086110 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Infinity Discovery, Inc.

20110086113 - Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents): The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma,... Agent:

20110086112 - Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.... Agent: Supergen, Inc.

20110086111 - Polymeric systems for the delivery of anticancer drugs: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions... Agent: Rexahn Pharmaceuticals, Inc.

20110086114 - Nasal composition: A nasal spray solution for use as a nasal spray and methods of using the solution are disclosed. The nasal spray solution moisturizes nasal passages and alleviates nasal dryness. The solution includes a hypotonic saline solution, wherein the saline solution is hypotonic with respect to cells of the nasal mucosa... Agent:

20110086115 - Vegetal-derived, water-absorbing composition: A vegetal-derived, water-absorbing composition comprising (i) a vegetal cholesterol derived semi-synthetically from one or a mixture of botanical materials from Dioscorea composita, Dioscorea terpinapensis, Dioscorea villosa and/or Trillium erectum, (ii) a non-animal, botanically-derived phospholipid comprising at least 20% phosphatidylcholine, (iii) a botanical oil or ester derivative at a concentration of... Agent:

20110086116 - Topical skin formulations comprising plant extracts: Disclosed are compositions and corresponding methods of their use that include extracts from Loropetalum chinensis, Camptotheca acuminate, Lonicera maackii, Washingtonia filifera, Artemisia parviflora, Glochidion lanceolaris, Polygonum hydropiper, Populus davidiana, Tsoongiodendron odorum, Trema angustifolia, Ficus tikoua, Pistacia chinensis, Zizyphus mauritiana, Garuga forrestii, Michelia figo, Sabina chinensis, Cuphea balsamona, Setaria palmifolia, Polygonum... Agent: Mary Kay Inc.

20110086117 - Antiseptic treat dip microemulsion: An aqueous antiseptic composition for eliminating microorganisms that cause Bovine mastitis in dairy animals is disclosed. The composition comprises about 10 to 50% by volume of lemongrass oil and at least one solubilizing agent for solubilizing the lemongrass oil. The composition also comprises about 10 to 30% by volume of... Agent: AxisIPHolding Pte Ltd

20110086118 - Composition for prevention of influenza viral infection comprising sumac extract, air filter comprising the same and air cleaning device comprising the filter: Disclosed are a composition for the prophylaxis of influenza viral infection comprising a sumac extract, an air filter coated with the same, and an air cleaner comprising the air filter. Having high inhibitory activity against influenza virus, the composition comprising a sumac extract can be applied to the prevention of... Agent: Woongjin Coway Co., Ltd.

20110086119 - Preparation for the relief of disease: A composition including (a) a Platelet Activating Factor (PAF) Inhibitor and (b) an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity. The composition is useful for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting.... Agent: Akl Technologies Limited

20110081292 - Methods of treating viral hepatitis: Disclosed are methods of treating viral hepatitis including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.... Agent:

20110081293 - Methods and compositions related to clot-binding lipid compounds: Disclosed are compositions and methods related to clot-binding head groups. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.... Agent: Regents Of The University Of California

20110081294 - Contrast agent for photoacoustic imaging and photoacoustic imaging method: A method of detecting a contrast agent for photoacoustic imaging provides a high signal intensity. In a contrast agent for photoacoustic imaging, each particle containing an inorganic material supports at least an organic dye having an absorption coefficient in the near infrared region by means of chemical bonding.... Agent: Canon Kabushiki Kaisha

20110081295 - Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration: The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the... Agent: Georgetown University

20110081296 - Systems and methods for identification of ciliopathy therapeutics: The invention provides systems and methods for identifying therapeutic targets for treating a disease including a ciliopathy. The invention further provides for drug discovery, and animal model systems related to drug discovery. The invention further relates to therapy of genetic disorders of the cellular cilia or basal bodies.... Agent: Rutgers, The State University Of New Jersey

20110081297 - Novel substituted pyrazoles, 1,2,4-oxadiazoles, and 1,3,4-oxadiazoles: The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET)... Agent:

20110081298 - Ratiometric bioluminescent sensor for imagining oxidative stress: This invention provides a novel ratiometric bioluminescent sensor and methods of use thereof. The bioluminescent sensor comprises two luminescent proteins that exhibit different characteristics associated a biological condition, and thereby illuminates differently in response to the biological condition. A ratio between the luminescence of the two luminescent proteins indicates a... Agent:

20110081299 - Cleaning and disinfecting agent: A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate,... Agent: Thonhauser Gmbh

20110081300 - Methods and composition for treating a material: A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. Also described are methods of making the composition.... Agent: Spectrum Enterprises, LLC

20110081301 - Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate: Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurised metered dose inhalers (pMDIs).... Agent: Chiesi Farmaceutici S.p.a.

20110081302 - Process for the obtention of purified heptafluoropropane: Process for the obtention of HFC-227ea having a reduced content of organic impurities, comprising at least subjecting a crude HPC-227ea to two distillation steps at different pressures.... Agent: Solvay S.a.

20110081303 - Teeth cleaning compound containing menthol with reduced bitter sensation: o

20110081305 - Compositions comprising a skin-lightening resorcinol and a skin darkening agent: The present invention relates to a composition comprising a skin-lightening resorcinol and a skin darkening agent. The composition may be topically applied to the skin, such as to treat signs of aging.... Agent:

20110081304 - Extracts of phyllanthus niruri: A method of making a low molecular weight fraction of Phyllanthus niruri is provided. Such low molecular weight fraction is particularly useful for treating the signs of skin aging.... Agent:

20110081307 - Kit comprising an alginate and a complexing agent in the form of a water-soluble salt: The present patent application relates to a keratin material coating kit comprising: a first composition comprising an aqueous phase, at least one alginic acid-based compound A and at least one compound B in the form of a water-soluble salt, the said compound being capable of releasing a gas on contact... Agent: L'oreal

20110081306 - Removable color layer for artificial nail coatings and methods therefore: The present disclosure relates to a nail coating system comprising a basecoat, a color layer, and a topcoat. The system of the present disclosure may be applied to natural and/or pre-existing artificial nail coatings. The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but... Agent: Creative Nail Design, Inc.

20110081308 - Extracts of phyllanthus niruri: A method of making a low molecular weight fraction of Phyllanthus niruri is provided. Such low molecular weight fraction is particularly useful for treating the skin, for example skin in need of treatment for signs of aging, for reducing inflammation, or for skin lightening.... Agent:

20110081309 - Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener: Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer, a micellar thickener, and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating a mammal by applying healthcare compositions of the present inventions to the mammalian body.... Agent:

20110081310 - Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof: Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating the human body by applying healthcare compositions of the present inventions to the body.... Agent:

20110081312 - 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine): An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.... Agent: Glaxosmithkline LLC

20110081311 - Complexes of il-15 and il-15ralpha and uses thereof: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol″ those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers,... Agent:

20110081313 - Mechanism of action of primary cell derived biologic: A method of treating an immune target that is suppressing the immune system and restoring the immune system, including the steps of administering an effective amount of a primary cell derived biologic, modifying populations of B and T cells in blood, activating regional lymph nodes, infiltrating an area adjacent to... Agent: Irx Therapeutics, Inc.

20110081314 - Antiviral phosphinate compounds: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences, Inc.

20110081315 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and... Agent: Intermune, Inc.

20110081316 - Pyrazole inhibitors of phosphatidylinositol 3-kinase: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110081317 - Enhancing gene transfer: Described herein are methods of improving the efficiency of gene transfer for a wide range of applications. Specifically provided are methods of increasing expression of an exogenous gene in a cell by contacting the cell with a vector comprising the exogenous gene and contacting the cell with a proteasome inhibitor,... Agent: University Of Rochester

20110081318 - Viral compositions and methods: Methods for producing recombinant viruses, compositions including the viruses, and uses for the compositions are described herein.... Agent:

20110081327 - Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection: A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an... Agent:

20110081319 - Composition and use of phyto-percolate for treatment of disease: This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease state.... Agent:

20110081320 - Treatment/cure of autoimmune disease: An embodiment entails administering an effective amount of a product such as a protease or a source of a protease that destroys or deactivates an immunogen, mimic or antigen specific to a particular autoimmune disease before it encounters the immune system of a patient.... Agent: Nubiome, Inc.

20110081328 - Use of selected lactic acid bacteria for reducing atherosclerosis: Strains of lactic acid bacteria selected for their capability of increasing the BSH-activity and consequently lowering serum LDL-cholesterol, and simultaneously decreasing the pro-inflammatory cytokine TNF-α levels, for prophylaxis and/or treatment of atherosclerosis and other cardiovascular diseases, a method of selecting such strains, and products containing such strains.... Agent:

20110081324 - Collagen peptide conjugates and uses therefor: Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of... Agent: Purdue Research Foundation

20110081326 - Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same: Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing.... Agent: Escape Therapeutics, Inc.

20110081322 - Elastin producing fibroblast formulations and methods of using the same: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests... Agent:

20110081323 - Methods and compositions for organ and tissue functionality: Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or... Agent: Dask Technologies, LLC

20110081325 - Novel treatment of heart diseases: Provided is a novel therapeutic approach for the treatment of heart failure and diseases associated therewith. In particular, vinca alkaloids are used for improving the viability of cardiomyocytes and preventing myocardial infarction.... Agent: Axiogenesis Ag

20110081321 - Omentum as a source of stromal/stem cells and medical treatments using stromal/stem cells: Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue... Agent: Loyola University Chicago

20110081329 - Amino acid compositions: Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanie, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histindine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric... Agent:

20110081330 - Compositions of fat-soluble active ingredients containing gum ghatti: The present invention relates to compositions containing plant gums and one or more fat-soluble active ingredients, wherein the composition comprises less than 40 weight-% oil, based on the total composition in dry matter. These compositions can be used for the enrichment, fortification and/or coloration of food beverages, animal feed, cosmetics... Agent:

20110081331 - Cancer therapy: The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.... Agent: Peter Maccallum Cancer Institute

20110081332 - Treatment of non-alcoholic steatotic hepatitis (nash): The present invention relates to a method for treating non-alcoholic steatotic hepatitis (NASH) in a subject by administering an effective amount of a lipoprotein lipase (LPL) therapeutic to the subject. The LPL therapeutic is advantageously a S447X protein or a derivative or variant thereof, or a nucleic acid encoding such... Agent: Amsterdam Molecular Therapeutics (amt)IPB.v.

20110081333 - Apparatus and system for treatment and prevention of bags under eyes: A simple, safe and effective invention devices for treating bags under the eyes pressure exerting glasses devices, compress badges, bag pressure adhesive strips, cosmetic pressure adhesive strips; to be put on to prevent, and to reduce the bags under the eyes. They are designed to apply antiwrinkle and other cosmetic... Agent:

20110081334 - C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5... Agent:

20110081335 - Processing biomass: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.... Agent: Xyleco, Inc.

20110081336 - Processing biomass: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.... Agent: Xyleco, Inc.

20110081337 - Function of gpr4 in vascular inflammatory response to acidosis and related methods: The present invention relates to methods for the treatment of inflammation. Specifically, disclosed herein are methods to inhibit vascular inflammatory responses by inhibiting the proton-sensing GPR4 receptor. Such methods can be utilized, most preferably, in pharmaceutical compositions to modulate inflammation in acidosis-related diseases.... Agent:

20110081342 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20110081341 - Immunopotentiative composition: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods... Agent: Tasuku Honjo

20110081338 - Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation: The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.... Agent: Chelsea Therapeutics, Inc.

20110081340 - Methods for treating disease using an anti-il-21 receptor antibody: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an... Agent: Zymogenetics, Inc.

20110081339 - Methods of using il-17 receptor a antibodies: The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.... Agent: Amgen Inc.

20110081344 - Soluble zcytor 11 cytokine receptors: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding... Agent: Zymogenetics, Inc.

20110081343 - Vaccines directed to langerhans cells: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one... Agent: Baylor Research Institute

20110081347 - Antibodies with altered binding to fcrn and methods of using same: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory... Agent: Macrogenics, Inc.

20110081346 - B7 family member zb7h6 and related compositions and methods: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are... Agent: Zymogenetics, Inc.

20110081345 - Single chain fc, methods of making and methods of treatment: The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule.... Agent:

20110081349 - Allergenic latex protein: The present invention relates to a protein found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it. The invention provides for the process of isolating and purifying the protein and describes the characteristics of the protein, including its molecular weight, isoelectric point,... Agent:

20110081351 - Antihuman baff antibody: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal... Agent: Kowa Company, Ltd.

20110081348 - Fungal signalling and metabolic enzymes: Method of identifying an anti-fungal agent which targets as an essential protein or gene of a fungus comprising contacting a candidate substance with (i) a protein which comprises the sequence shown by SEQ ID NOS: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45,... Agent:

20110081352 - Immunogenic peptides and methods of use for treating and preventing cancer: Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Service

20110081350 - Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions: s

20110081353 - Antibody against the csf-1 r: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.... Agent:

20110081354 - Anti-ctla-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof: The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies... Agent: Medarex, Inc.

20110081356 - Anti-cancer drug: The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody.... Agent: The University Of Tokyo

20110081355 - Methods of diagnosing and treating conditions using anti-il-6 antibodies: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.... Agent:

20110081358 - Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection: The present invention provides a purified multimeric complex from P. gingivalis. The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.... Agent: The University Of Melbourne

20110081357 - Chimeric vaccine for haemophilus influenzae-induced disease: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins... Agent: Nationwide Children's Hospital, Inc.

20110081359 - Alpha 5 beta 1 and its ability to regulate the cell survival pathway: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma,... Agent:

20110081361 - Antibodies that bind interleukin-4 receptor: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4... Agent:

20110081360 - Human g-protein chemokine receptor (ccr5) hdgnr10: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells,... Agent: Human Genome Sciences, Inc.

20110081362 - Treatment of cancer: Described herein are methods based, in part, on the discovery of genes or gene products that can be down-modulated to inhibit the growth and survival of a cell, such as a cancer cell. In one embodiment, the genes or gene targets are preferentially expressed in a cell having an activating... Agent: The Brigham And Women's Hospital, Inc.

20110081363 - Compositions and methods for biological sample storage: Compositions and methods are disclosed for substantially dry storage at ambient or elevated temperatures of biological samples such as nucleic acids, proteins and cells in a form from which the samples can be substantially recovered, using a dissolvable or dissociable dry storage matrix comprising a borate composition and a stabilizer... Agent: Biomatrica, Inc.

20110081365 - Compounds and compositions as tlr activity modulators: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine... Agent: Novartis 35

20110081366 - Immunostimulatory nucleic acid molecules: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.... Agent: University Of Iowa Research Foundation

20110081367 - Influenza sequences: We provide a nucleic acid sequence as shown in Table D1 or Table D2, or a variant, homologue, derivative or fragment thereof. A combination of two or more sequences is also provided. The nucleic acid sequence or combination may be used for detection of influenza or discrimination between strains of... Agent: Veredus Laboratories Pte Ltd

20110081364 - Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of Aurora protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20110081368 - Protein vaccines against poxviruses: The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having... Agent:

20110081369 - Immune modulation with death receptor-induced apoptosis: This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes... Agent: University Of Louisville Research Foundation, Inc.

20110081370 - Methods and compositions for modulating immune tolerance: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.... Agent: Government Of The Us, As Represented By The Secretary, Dept Of Health And Human Services

20110081371 - Angiotensin peptide-carrier conjugates and uses thereof: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of... Agent: Cytos Biotechnology Ag

20110081372 - Cosmetic compositions and container therefor: A self-standing container holds particles of a cosmetic composition. The container may be cup-shaped or box-shaped, for example, and made of laminated paper or polystyrene. When ready to use, the user opens the container and adds liquid or gel to mix with the dry particles to form a moist cosmetic... Agent:

20110081373 - Attenuating mutations in the influenza a virus nep(=ns2) protein: The invention provides an isolated attenuated recombinant influenza virus comprising a gene segment comprising a mutant NS2 protein gene, wherein the NS2 protein has at least two substitutions that do not substantially alter the in vitro replication of the virus but are associated with attenuation of the virus in vivo,... Agent: Warf - Wisconsin Alumni Research Foundation

20110081375 - Chimeric adenoviral vectors: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.... Agent: Vaxart, Inc.

20110081374 - Recombinant avian paramyxovirus vaccine and method for making and using thereof: The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting... Agent:

20110081376 - Method for using inactivated japanese encephalitis virus particles as adjuvant: A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells,... Agent: The Chemo-sero-therapeutic Research Institute

20110081377 - Aerosolized genetic vaccines and methods of use: The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols.... Agent: The United States, As Represented By The Secretary Department Of Health And Human Services

20110081378 - Composition comprising iscom particles and live micro-organisms: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at... Agent: Isconova Ab

20110081379 - Purification method and method of producing vaccine: A method of purifying a virus or viral antigen from a sample solution containing the virus or viral antigen is provided. The method comprises: preparing sintered powder of hydroxyapatite, wherein a specific surface area of particles of the sintered powder is in the range of 2.0 to 11.0 m2/g; bringing... Agent: Hoya Corporation

20110081380 - Stabilizing excipient for inactivated whole virus vaccine: m

20110081381 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions... Agent: Chrontech Pharma Ab

20110081382 - Treatment and prevention of tuberculosis: The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related diseases. The composition useful for these purposes is disclosed, including the methods of using said composition.... Agent: Immunitor Usa Inc.

20110081383 - Live attenuated leishmania vaccines: Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation... Agent: Institute Of Pathology (icmr)

20110081385 - Compositions and methods for sleep regulation: Compositions and methods for the regulation of sleep and circadian rhythms are provided. The compositions are nutritional supplements containing melatonin and one or more vitamins that enhance the effectiveness of melatonin. Preferred vitamins include folic acid, riboflavin (vitamin B2), cobalamin (vitamin B12) or pyridoxine (vitamin B6). The compositions beneficially and... Agent: Lifescape Biosciences Inc.

20110081386 - Controlled release of active agents from oleosomes: The release rate of an active agent from oleosomes can be modulated by formulation of the oleosomes with a release control agent, such as a multihydric alcohol. In this context, oleosomes containing an active agent may be used in the preparation of a variety of formulations, including formulations for topical... Agent: Sembiosys Genetics, Inc.

20110081384 - Methods of wound care and treatment: Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface... Agent: Revalesio Corporation

20110081390 - Anhydrous, transfer-resistant cosmetic lip compositions: The anhydrous cosmetic compositions of the present invention provide a durable film after application that resists degradation over time. The anhydrous cosmetic composition includes an aminosilicone, an organosiloxane resin, and a volatile carrier. The anhydrous cosmetic composition can also be packaged with a topcoat product.... Agent:

20110081389 - Composition comprising a mixture of active principles, and method of preparation: Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.... Agent: Ethypharm

20110081388 - Detergent composition: A detergent composition having from 1% to 50% by weight of anionic surfactant and from 0.1% to 30% by weight of sudsing particles. The sudsing particles have: an average per number length of from 50 nm to 50 μm, an average per number width of from 1 nm to 500... Agent:

20110081387 - Liposomes encapsulating an oxazolidin-2-one compound: d

20110081392 - Shampoo compositions: The invention relates to a granulated personal care shampoo comprising a shampoo composition comprising at least one surfactant agglomerated with a water-soluble, water-dispersible or water-insoluble solid particulate carrier. Preferably, the shampoo composition additionally contains a conditioner preferably comprising an organopolysiloxane. The granulated shampoo of the invention can dissolve readily with... Agent:

20110081391 - Skin-covering sheet for impregnation with cosmetic preparation and face mask: A skin-covering sheet for impregnation with a cosmetic preparation according to the present invention includes a non-woven fabric in which a splittable conjugate fiber containing at least two components as viewed in fiber cross-section, namely a polyethylene component and another polymer component, and a hydrophilic fiber are blended, and hydroentangled.... Agent: Daiwabo Polytec Co., Ltd.

20110081393 - Cooling sensation agent composition, sensory stimulation agent composition and use of the same: Disclosed is a cooling sensation agent composition or sensory stimulation agent composition which contains at least one of diester compounds of dicarboxylic acid represented by the formula (1) wherein A represents CH2 or CH═CH, n represents an integer of 0 to 4 when A is CH2, or 1 when A... Agent: Takasago International Corporation

20110081394 - Methods of attaching a molecule-of-interest to a microtube: Provided is a method of attaching a molecule-of-interest to a microtube, by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming... Agent: Technion Research & Development Foundation Ltd.

20110081396 - Glass ceramic scaffolds with complex topography: A bioactive and bioresorbable scaffold including a glass-ceramic material including fluoroapatite and hydroxyapatite doped with about 1-5 wt.% niobium oxide that is shaped into a scaffold is described. The glass-ceramic material has high crystallinity and a complex topography which provide it with greater structural strength and bioresorbability. Methods of preparing... Agent: The Ohio State University Research Foundation

20110081397 - Mesh implant: The present disclosure relates to implants including a porous substrate, a first hydrogel precursor, a second hydrogel precursor and a mesh. The first and second hydrogel precursors are applied to the porous substrate. The mesh has a first portion in contact with the porous substrate and a second portion exposed... Agent: Tyco Healthcare Group Lp

20110081398 - Multi-mechanism surgical compositions: The present disclosure provides hydrogel compositions having multiple gelation mechanisms. The composition includes at least one component which forms a hydrogel, in combination with a second component which includes a self-assembling peptide capable of forming a self-assembled macromer.... Agent: Tyco Healthcare Group Lp

20110081399 - Surface modification of nitinol: Disclosed herein are methods of modifying a nitinol surface by using abrasive blasting techniques. The surface modification can be performed by abrasively blasting the surface and delivering at least one dopant from one or more fluid jets to cause the at least one dopant to impregnate and/or coat the nitinol... Agent: Enbio Limited

20110081395 - Ultra-nanocrystalline diamond as a biomaterial for enhancing proliferation and differentiation of neural stem cells: Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film... Agent: National Tsing Hua University

20110081400 - Nutritional composition for bariatric surgery patients: m

20110081401 - Dermal patch comprising chondrus crispus extract: The present invention relates to masks for dermal treatment or “patches”, based on a vegetal matrix, particularly red algae (Chondrus crispus) extract rich in polymeric thickeners. The invention relates also to compositions, in particular cosmetic and dermopharmaceutical formulations, to the process for their industrial preparation and to their use in... Agent: Biophil Italia S.p.a.

20110081406 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.... Agent: Morehouse School Of Medicine

20110081407 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.... Agent: Morehouse School Of Medicine

20110081408 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.... Agent: Morehouse School Of Medicine

20110081402 - Cosmetic base comprising collagen-modified liposome and skin cosmetic containing the same: The affinity of collagen for the skin and its persistence on the skin are improved without destroying the triple helical structure inherent in collagen to thereby improve its ability to retain the moisture of the skin and increase the amount of bound water when such collagen is used as a... Agent:

20110081403 - Histone octamers for increased nucleic acid transfer: The present invention provides reconstituted histone octamers with multiple modifications (e.g. acetylation of all histones and trimethylation of histone H3K4) assembled onto plasmids for increased transcription post-transfection using our unique bi-lamellar invaginated liposomes (BIVs) to more effectively recruit the transcriptional machinery of human cancer cells post-transfection and substantially increase the... Agent: Gradalis, Inc.

20110081404 - Novel liposome compositions: The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases.... Agent: Mebiopharm Co., Ltd.

20110081409 - Selective inhibitors of histone deacetylase: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.... Agent:

20110081405 - Zeolite formulation and use thereof for the prevention and therapy of diseases caused by infections with herpes simplex virus type 1 and type 2: s

20110081411 - Orally administered corticosteroid compositions: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.... Agent:

20110081412 - Orally disintegrable tablets: An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and... Agent: Takeda Pharmaceutical Company, Limited

20110081410 - Therapeutic agent for local inflammation: The agents of the present invention comprise, as a main ingredient, a polyvalent metal inorganic-salt nanocapsule which encapsulates a retinoid such as retinoic acid. The agents could penetrate into a joint when applied to the skin and induce hyaluronic acid production in a synovial membrane or chondrocyte. Moreover, application of... Agent: St. Marianna University, School Ofmedicine

20110081413 - Pharmaceutical compositions comprising phosphate-binding polymer: The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion... Agent:

20110081414 - Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability: Comestible materials encapsulated by a film-forming composition including a plant protein source and methods of forming the same are provided. The film-forming composition affects the site of digestion of the comestible material within the digestive tract of an animal or a human thereby allowing the material to be most effectively... Agent: Kansas State University Research Foundation

20110081415 - Coating apparatus: A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar... Agent: Taisho Pharmaceutical Co., Ltd

20110081416 - Ordered mesoporous silica material: A process for preparing a 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size in the range of 4 to 30 nm comprising the steps of: preparing an aqueous solution comprising an alkali silicate solution; preparing an aqueous solution comprising a poly(alkylene oxide) triblock copolymer and a buffer... Agent: Formac Pharmaceuticals N.v.

20110081417 - Surgical compositions: The present disclosure relates to multi-component hydrogels. The hydrogels may include a natural component having nucleophilic functional groups as well as an electrophilic component. In embodiments, at least one of the components may be branched, having drugs, antibodies, enzymes, and the like incorporated therein, which may react with at least... Agent: Tyco Healthcare Group Lp

20110081419 - Ion exchange resin treated to control swelling: The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the... Agent: Coating Place, Inc.

20110081418 - Transdermal absorption enhancer: An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations... Agent: Nanoegg Research Laboratories, Inc.

20110081420 - Method of forming prolonged-release injectable steroids: A method of forming prolonged-release injectable steroids. The method includes providing a steroid composition, a bioabsorbable polymer and a solvent. A solution is formed from the steroid composition, the bioabsorbable polymer and the solvent. Droplets are formed from the solution. The solvent is removed from the droplets to cause the... Agent: Zyga Technology, Inc.

20110081421 - Methods of regulating renalase (monoamine oxidase c): The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can... Agent: Yale University

20110081422 - Prolonged release of local anesthetics using microparticles and surgery applications: Methods and compositions for providing long term pain relief in, for example, surgery recovery, including injecting a composition comprising a plurality of microparticles having different sizes and at least one local anesthetic loaded into the microparticles at different loading levels. Extended prolonged blockage of nerve action in sheep testing was... Agent: Capsulated Systems Inc.

20110081423 - Tissue stabilization for heart failure: Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium,... Agent:

20110081424 - Nutritional composition for bariatric surgery patients: A ready-to-consume liquid nutritional composition which is particularly suitable for use by morbidly obese patients pre- and post-bariatric surgery. The composition comprises an energy content between 80-160 kcal/100 ml, a protein content between 40-80 En %, a digestible carbohydrate content between 0-30 En %, a fat content between 5-40 En... Agent:

20110081425 - Pesticidal compositions and methods: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.... Agent: W. Neudorff Gmbh Kg

20110081426 - Aminothiazole modulators of beta-3-adrenoreceptor: The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110081427 - Nitroxyl progenitors in the treatment of heart failure: Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused... Agent: Johns Hopkins University

20110081428 - Use of thioflavin-like compounds to increase life span and/or health span: The present invention provides a method of using thioflavin and functionally similar compounds to increase life span and/or health span.... Agent: The Buck Institute For Age Research

20110081429 - Composition for external use: The present invention provides an externally applied composition capable of enhancing a stimulatory effect of an essential oil on IGF-1 secretion, the composition including (A) essential oil; and (B) at least one member selected from the group consisting of purine substances and salts thereof. Further, the present invention provides an... Agent:

20110081431 - Compositions comprising an nfkb-inhibitor and a non-retinoid collagen promoter: The present invention relates to a composition comprising an NFκB-inhibitor and a non-retinoid collagen promoter.... Agent:

20110081430 - Compositions comprising an nfkb-inhibitor and a tropoelastin promoter: The present invention relates to a composition comprising an NFκB-inhibitor and a tropoelastin promoter, and methods of treating signs of skin aging using said compositions.... Agent:

20110081432 - Extracts of phyllanthus niruri: A method of making a low molecular weight fraction of Phyllanthus niruri is provided. Such low molecular weight fraction is particularly useful for treating the skin, for example skin in need of treatment for signs of aging, for reducing inflammation, or for skin lightening.... Agent:

20110081433 - Compositions comprising an anti-inflammatory blend: The present invention relates to a composition comprising an NFkB-inhibitor and an anti-inflammatory compound. The anti-inflammatory compound is not an NFkB-inhibitor and has an IC50 of about 70 μg/ml or less.... Agent:

20110081434 - Extract of coptidis rhizoma and novel use thereof in treating respiratory disease: A composition for suppressing cough, removing sputum, preventing and/or treating a respiratory disease comprising an extract of Coptidis rhizoma or a combined extract of Coptidis rhizoma with ivy leaf as an active ingredient, and a method of suppressing cough, removing sputum, and/or preventing and/or treating respiratory disease using the composition,... Agent: Ahn-gook Pharmaceutical Co. Ltd

20110081435 - Stabilized oleosome preparations and methods of making them: The physical stability of oleosomes is preserved in a composition by introducing a multihydric alcohol and an acid that can reduce the pH of the composition of less than 6. The resultant composition can be useful in the manufacture of cosmetic, food, and pharmaceutical products, among others.... Agent: Sembiosys Genetics, Inc.